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ABSTRACT
LIVER KINASE B1 ISOFORM EXPRESSION AS A REGULATOR OF T CELL
PHENOTYPIC STABILITY
SEPTEMBER 2020
HEATHER L SHERMAN, B.S., STATE UNIVERSITY OF NEW YORK AT
BINGHAMTON
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Dr. Lisa M. Minter
Following activation, CD4 T cells undergo extensive metabolic and transcriptional changes
to respond to external cues and differentiate into T helper (Th) cell subsets. This differentiation
process was originally perceived to be terminal. However, it has been shown that T cells exhibit
plasticity between subsets in the context of highly inflammatory environments. This phenomenon
is especially prevalent in autoimmune conditions such as colitis and multiple sclerosis in which
high levels of IL-6 promote considerable plasticity between regulatory T (Treg) cells and Th17
cells. Herein we show that Liver Kinase B1 (LKB1), a metabolic sensor that enforces energypreserving mechanisms such as fatty acid oxidation (FAO), is spliced into its short isoform in Th17
cells but not in induced (i)Tregs. We demonstrate that, in Th17 cells, heterogeneous nuclear
ribonucleoprotein L-like (hnRNPLL) binds to transcripts of Stk11, which encodes LKB1, and this
correlates with alternative splicing into its short splice variant (Stk11S).When we neutralize
hnRNPLL function using a cell-penetrating antibody, we observe diminished Stk11S expression.
We further show that hnRNPLL and Stk11S, both, are regulated by the T cell-specific kinase,
Protein Kinase C theta (PKC) in Th17 cells. We provide additional evidence that, in iTregs
exposed to IL-6, Prkcq, Stk11S, and Rorc are all upregulated, suggesting iTreg-Th17 plasticity is
vii

induced in response to IL-6 and culminates in Stk11 splicing downstream of PKC Finally, we
demonstrate a link between Stk11 splicing and Th17 metabolism, showing that functionally
inhibiting hnRNPLL modulates expression of the key glycolytic enzyme, Hexokinase 2, and
inhibiting glycolysis, in turn, modulates the expression of Stk11S. Our data reveal an as-yetundescribed outside-in signaling pathway downstream of IL-6 that acts through PKC and
hnRNPLL to regulate splice variants of Stk11 in Th17 cells. Furthermore, we show for the first
time that this pathway can also be initiated in iTregs exposed to IL-6, providing mechanistic insight
into iTreg-Th17 plasticity.
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CHAPTER 1
INTRODUCTION

1.1 T cell activation and differentiation
T cells are activated by antigen encounter and differentiate to illicit various effector
responses. The details of T cell activation, differentiation, and the regulation of T cell
responses by regulatory T cells will be discussed herein.
1.1.1 T cell activation
Mature naïve T cells circulate through secondary lymphoid organs where they
encounter antigen presenting cells (APC). To maintain the naïve state without cell death,
the cell requires tonic T cell receptor (TCR) signaling and IL-7 stimulation (Chapman et
al., 2019). The APC expresses major histocompatibility complex (MHC) proteins loaded
with peptide from self-tissue or pathogens. T cells will become activated through
engagement of the peptide:MHC complex with the T cell receptor which is associated
with CD3 (Hoefig and Heissmeyer, 2018). To achieve sustained activation, proliferation
and subsequent differentiation, T cells need to receive two additional signals. The second
signal is initiated through the interaction of CD28, on the T cell membrane, and CD80 or
CD86, on the APC surface. CD28 stimulation is crucial to prevent the onset of anergy and
for the activation of signaling cascades modulated by kinases such as Protein Kinase Cθ
(PKCθ; Berg-Brown et al., 2004).
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The interactions between TCR:MHC and CD28:CD80/86 will promote the
formation of an immunological synapse between the T cell and APC. The synapse
requires rearrangement of the T cell cytoskeleton and movement of the lipid rafts to the
point of contact. Lipid rafts are lipid microdomains rich in glycosphingolipids that act as
docking sites for signaling proteins (Lucas et al., 2004). Several signaling cascades are
activated downstream of CD3 and CD28 that culminate in the activation of the NF-B,
AP-1, and NFAT transcription factors which are necessary for complete T cell activation.
These transcription factors will drive the expression of IL-2, a T cell survival and growth
factor, (Hoefig and Heissmeyer, 2018). In addition to CD3 and CD28 stimulation, T cells
require cytokine signaling to sustain their survival, proliferation, and aid in their
differentiation into effector cells (Zhou et al., 2009). Figure 1 illustrates the three signals
needed for complete T cell activation.
1.1.2 Cytokine signaling
Cytokines signal through cognate receptors which is bound intracellularly to Janus
Kinase (JAK). JAK is activated by ligand binding and drives JAK tyrosine
autophosphorylation and phosphorylation of the intracellular domain of the cytokine
receptor. This tyrosine phosphorylation creates a docking domain for signal transducers
and activators of transcription (STAT) proteins to bind to the cytokine receptor and, thus,
allows JAK kinases to phosphorylate STAT proteins. Tyrosine phosphorylation creates a
SH2 domain on the STAT protein, which allows it to dimerize with other STATS. Once
dimerized, STAT proteins can translocate to the nucleus and bind gene promoters to
complete the cytokine signal (Leonard and O’Shea, 1998).
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There are 4 different JAK kinases and 7 different STAT proteins which can be
combined to elicit different functional outcomes, specific to the cytokine receptor signal
propagation (Dodington et al., 2018). Specificity of the cytokine signaling is mediated by
unique STAT protein dimers which dictate downstream gene expression, and activation
of specific T cell effector programs (O’Shea and Plenge, 2012). A schematic of JAK/STAT
signaling is illustrated in Figure 2.
1.1.3 CD4 T cell differentiation
Activated CD4 T cells differentiate into helper T cells to elicit specific immune
responses to different types of pathogens (Zhu et al, 2018). There are several different
helper T cell subsets; the main subsets are depicted in Figure 1.3. Cytokines produced
by APCs signal to the newly stimulated T cell to influence which helper T cell subset
program is activated. Specific cytokines, signaling through JAK/STAT, upregulate
signature transcription factors which are required for effector functions characteristic of
each helper subset (Schmitt and Ueno, 2015; Zhu et al, 2018).
The T helper (Th) 17 cell program is initiated by IL-6 signaling through the IL-6
receptor and subsequent activation of JAK1 and STAT3. IL-6 is an 80kDa protein
produced by APCs, endothelial cells, and monocytes (Schaper and Rose-John, 2015).
IL-6 is a pleiotrophic cytokine that can signal to induce different processes ranging from
inflammation to bone remodeling (Tanaka et al., 2014). The IL-6 receptor (IL-6R) is a type
I transmembrane receptor found on immune cells, such as CD4 T cells and monocytes.
Upon ligand binding, the IL-6R associates with a longer transmembrane protein, gp130,
which is constitutively bound to a JAK protein. Once gp130 and the IL-6R bind, JAK
proteins are autophosphorylated, leading to subsequent STAT3 activation (Schaper and
3

Rose-John, 2015). STAT3 dimers will bind to the Rorc and Il17 promoters inducing the
effector functions of Th17 cells. The Th17 program also needs activation through
transforming growth factor beta (TGF-β; Zhu et al, 2017). TGF-β will also induce the
activation of RORγT to further perpetuate IL-17 production and stability of the Th17
phenotype (McGeachy and Cua, 2008).
Th17 cells secrete IL-17 to primarily combat extracellular bacteria which are found
at mucosal surfaces (Ivanov et al., 2006; Zhu, 2018). IL-17 will promote more Th17 cell
polarization, B cell responses, induce the production of pro-inflammatory chemokines to
recruit neutrophils to the site of infection, and program the macrophage response.
Additionally, the pro-inflammatory profile induced by IL-17 signaling will propagate an
inflammatory response through non-immune cells such as endothelial and epithelial cells
which can secrete antimicrobial peptides (Iwakura et al., 2011). Th17 cells are thus the
orchestrators of immunity within the mucosal compartment.
1.1.4 Thymic and peripheral regulatory T cell development
Regulatory T cells (Treg) are crucial for limiting the extent of an immune response
and preventing immune attack on self-tissue. Naturally occurring Tregs (nTregs) arise
from the thymus or can be induced in the periphery (iTregs). Tregs suppress other
immune cells through a variety of mechanisms mediated by the signature transcription
factor, forkhead box p3 (Foxp3; Deng et al., 2019; Kitagawa and Sakaguchi, 2017). Foxp3
mutations lead to the immune dysregulation, polyendocrinopathy, enteropathy, X-linked
(ipex) syndrome which causes widespread autoimmunity due to Treg deficiency. Foxp3
expression can be induced by Foxp3, itself, or by GATA-3 or STAT5 (Ohkura et al., 2012).
Foxp3 expression is regulated at its promoter through three conserved, noncoding
4

sequence (CNS) regions (Kanamori et al., 2016). CNS2, also known as the Treg cellspecific demethylated region, or TSDR, must be demethylated to sustain Foxp3
expression levels (Ferreira et al., 2019). Prior to antigenic stimulation, Treg cells are
characterized as central Treg cells which express the chemokine receptor, CCR7, and
CD62L which allows for tissue migration. Treg cells receive antigen stimulation as effector
T cells do in the context of peptide:MHC and CD28 stimulation. Upon stimulation, Treg
cells become effector Tregs which downregulate CCR7 and CD62L and subsequently
upregulate CD44 (Rothstein and Camirand, 2015).
Naturally occurring Tregs develop in the thymus during negative selection when
single-positive CD4 thymocytes are challenged with antigens expressed by the
transcription factor Aire. If the thymocytes are highly reactive to any self-antigen, the cell
will undergo apoptosis. A moderate reaction to self-antigen induces the upregulation of
CD25 and Foxp3 (Owen et al., 2019). These cells will exit to the periphery and circulate
until they are activated (Rothstein and Camirand, 2015). Figure 1.4 illustrates the
generation of nTregs.
iTreg cells are generated by TGF-β and IL-2 signaling, and can be induced both in
vivo and in vitro. There are specific organs, such as the intestines and the placenta, which
are highly enriched in iTreg cells that suppress immune responses against food antigens
and which mediate fetal rejection, respectively. The upregulation of Foxp3 in iTreg cells
is mediated by TGF-β signaling to stimulate the CNS1 region. Whereas IL-2 signaling in
these cells will upregulate CD25 which is necessary Treg survival and suppressive
function (Kanamori et al., 2016).
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1.1.5 Treg-mediated suppression
Treg cells can suppress both APCs and effector T cells using several different
mechanisms. The preference for suppressing one cell type over another seems to be
tissue- and target cell-dependent. In addition, Tregs can upregulate cytokine receptors to
make them more suppressive against specific cell types (Duhen et al., 2012). One such
suppressive mechanism is infectious tolerance which is mediated by transferring
suppressive functions from Tregs to another cell type. The most conventional form of this
type of suppression, is through the release of anti-inflammatory cytokines (Ferreira et al.,
2019). It was originally thought that Treg cells only secrete the cytokine, IL-10; however
there is emerging evidence that Tregs can also secrete the anti-inflammatory cytokine,
IL-35 (Shevach, 2009). Signaling through the IL-10 receptor activates TYK2, a JAK
kinase, which further activates SHP-1, a phosphatase, inhibiting processes downstream
of CD28 ligation (Boonpiyathad et al., 2019). Another mechanism by which Tregs can
inhibit effector T cells is by acting as a sink for IL-2 in the surrounding environment. This
leaves less IL-2 available for effector T cells and in the absence of sufficient IL-2 signaling,
effector T cells will undergo apoptosis. Tregs can also suppress effector T cells via direct
lysis of the cell through the actions of Granzyme A or B. However, it is not clear whether
APCs or effector T cells, or both are lysed by Treg cells, nor is it clear through which
enzyme, Treg-mediated cytolysis occurs (Shevach, 2009).
Treg cells also express immune checkpoint molecules such as cytotoxic Tlymphocyte associated protein-4 (CTLA-4), Programmed Cell Death-1 (PD-1),
lymphocyte activating gene-3 (LAG3), and T cell immunoglobulin and immune receptor
tyrosine-based inhibitory motif domain (TIGIT). CTLA-4 is a homologue of CD28 and can
6

engage CD80 or CD86 on APCs. These interactions can affect the APC in two ways:
creating a physical barrier to CD28 ligation on the T cells and causing downregulation
CD80 and CD86 on the APC. In the absence of CD80 or CD86 expression, the APC can
still engage the TCR on effector T cells, but without CD28 ligation the T cell will undergo
anergy. CTLA-4 engagement with CD80/CD86 can also induce the APC to secrete
indoleamine 2,3-dioxygenase (IDO) which converts tryptophan into pro-apoptotic
proteins, thus killing surrounding effector T cells (Shevach, 2009). Tregs also suppress
through Programmed Cell Death Protein-1 (PD-1) receptor interaction with its two ligands,
Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2). PD-1, on the Treg, will bind its
cognate ligand on the APC, inducing APC cell death. Additionally, PD-1 on the Treg
further enhances Foxp3 expression and the subsequent effector function of the Tregs
(Gianchecchi and Fierabracci, 2018). LAG3 is a homolog of CD4 that is thought to bind
MHC class II proteins on dendritic cells. LAG3-MHC class II binding blocks dendritic cell
maturation, making them unavailable to promote T cell activation (Shevach, 2009). TIGIT
can also be expressed on Tregs and competes with CD226 to bind CD155 on dendritic
cells. Engagement of TIGIT with CD155 inhibits dendritic cell maturation (Joller et al.,
2014; Kurtulus et al. 2015). TIGIT-expressing Tregs are highly suppressive, express
higher levels of Foxp3, PD-1, CTLA-4, and secrete more IL-10 (Kurtulus et al., 2015).
Interestingly, these Tregs are autophagy-dependent which has been shown to be
important in Treg survival (Le Texier et al., 2016).
1.2 T cell metabolism
T cells will undergo metabolic changes during its lifetime to accommodate for its
energetic demands. Additionally, different subsets of T cells can engage different
7

mechanisms of energy production but tend to rely more heavily on one metabolic
pathway. Ultimately the goal is to produce acetyl-coA to fuel the Citric Acid Cycle (TCA)
and electron carriers for oxidative phosphorylation (OXPHOS) to produce ATP. This can
be done through several processes, as shown in Figure 1.5 (Galgani et al., 2015). In the
next section, preferences in energy metabolism for naïve, effector, and regulatory T cells
will be discussed.
1.2.1 Metabolism of the naïve T cell
Naïve T cells are metabolically quiescent until they encounter antigen. During their
quiescence, T cells favor energy-preserving metabolic processes. Instead of importing
glucose or amino acids the cell will breakdown intracellular stores of these nutrients to
fuel mitochondrial ATP production through oxidative phosphorylation (OXPHOS) and the
tricarboxylic acid (TCA) cycle. It is crucial to maintain IL-7 signaling during quiescence,
as IL-7 promotes the breakdown of necessary molecules to fuel OXPHOS (Chapman et
al., 2019). After glycolysis, pyruvate is further modified into acetyl-coA by pyruvate
dehydrogenase. Acetyl-coA will be fed into the TCA cycle to generate the electron carriers
FADH2 and NADH. These electron carriers are used for OXPHOS to generate ATP
(Lochner et al., 2015; Ma et al., 2017; Galgani et al., 2015; Blagih et al., 2012).
1.2.2 Metabolic changes in the activated T cell
Upon activation, naïve T cells undergo a process known as the “Warburg Effect”,
depicted in Figure 1.6, which changes the cell’s primary means of energy production from
catabolism to anabolism (van der Windt and Pearce, 2012). T cells experience various
changes after activation to accommodate for increases in cell size, proliferation, and
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acquisition of effector functions. These changes require increased energy production and
the accumulation of biomass. A naïve T cell can break down its cellular components to
feed OXPHOS; however, this is a slow process and is not sufficient to fuel an effector
cell’s new energy requirements (Blagih et al., 2012).
The Warburg Effect allows cells to use glycolysis to convert glucose into lactate
under normal oxygen conditions. Most of the pyruvate generated by glycolysis in an
activated T cell is converted into lactate. As a byproduct of this lactate production, NAD+
is produced which is an electron carrier used in glycolysis and OXPHOS, thus speeding
up these processes. Furthermore, glucose-6-phosphate, a glycolysis intermediate, can
be shuttled to the pentose phosphate pathway which will aid in nucleic acid and aromatic
amino acid synthesis. The pentose phosphate pathway will also produce the reducing
agent NADPH which is important in biosynthesis pathways. In addition to glucose
metabolism, the activated T cell can also metabolize glutathione through glutaminolysis.
Glutamine will be converted into α-ketoglutarate which will be fed into the TCA cycle and
further generate ATP (van der Windt and Pearce, 2012).
CD28 engagement activates the Protein Kinase B (AKT)/ mammalian Target of
Rapamycin Complex 1 (mTORC1) pathway and induces several changes to initiate
anabolic metabolism. This includes the integration of the GLUT1 receptor (a glucose
transporter) on the cell surface to induce more glucose intake rather than breakdown
intracellular glucose stores. Other transporters activated by this pathway are CD71, for
transferrin, and CD98 for amino acids. mTORC1 will also activate Hypoxia Inducible
Factor 1α (HIF1α) which upregulates GLUT1 transcription. Additionally, mTORC1 will
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activate myelocytomatosis oncogene (MYC) which regulates glutamine uptake (Galgani
et al., 2015).
In addition to increased glycolysis, the activation of lipid synthesis enzymes is also
necessary. mTORC1 will relieve inhibition of fatty acid synthesis (FAS) through the
enzyme acetyl-CoA carboxylase 1 (ACC1; Galgani et al., 2015). mTORC1 promotes fatty
acid synthesis by blocking fatty acid oxidation (FAO) by inhibiting the rate-limiting enzyme
carnitine palmitoyltransferase 1 (CPT1a) and activating sterol regulatory element-binding
(SREBP) proteins. Fatty acid synthesis is favorable for biomass accumulation as fatty
acids are crucial to lipid raft synthesis, myristoylation, palmitoylation, and other functions
necessary for T cell activation and proliferation (Lochner et al., 2015). All together, these
pathways yield more energy and biomass accumulation to support the many new
processes initiated by the activated T cell.
1.2.3 Metabolic processes of regulatory T cells
Tregs differ in their metabolic requirements as compared to helper T cells. The
energy demands of Tregs are heavily reliant on TCA to fuel OXPHOS, rather than on
glycolysis. Tregs mainly use fatty acid oxidation (FAO) to generate acetyl-coA to fuel the
TCA cycle. Long chain fatty acids are attached to carnitine through CPT1a. Carnitine
shuttles the fatty acids to the mitochondria where it will be converted into acyl-coA via
carnitine palmitoyltransferase 2. The fatty acids will be further broken down and fed into
the TCA cycle, promoting energy production via TCA, and resulting in ATP production
through OXPHOS. This leads to increased reactive oxygen species (ROS) and increased
mitochondrial mass (Kempkes et al., 2019).
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Glycolysis can be very inhibitory to Treg suppression. Tregs have less GLUT1 on
their cell surface than helper T cells and the presence of GLUT1 correlates with reduced
Treg suppressive capacity. Furthermore, induction of glycolysis in Tregs decreases levels
of Foxp3 in these cells (Shi and Chi, 2019). Reciprocally, Foxp3 can downregulate
glycolysis by suppressing MYC to further enhance OXPHOS. Tregs rely heavily on
OXPHOS, as inhibiting Complex I in the electron transport chain led to less suppressive
Tregs (Angelin et al., 2017). However, Tregs also require some level of glycolysis for
proliferation and migration. Therefore, Tregs must maintain a balance between glycolysis
and FAO that will allow them to maintain suppressive capacity while also accommodating
their need for growth (Kempkes et al., 2019).
1.2.4 Metabolism and plasticity
After stimulation by TCR and CD28 signaling, the newly activated T cell will receive
cytokine signals from APC to achieve full activation. Differential cytokine signaling
induces the T cell to upregulate a specific differentiation program. This differentiation
process was originally perceived to be terminal. However, it has been shown that T cells
exhibit plasticity in the context of highly inflammatory environments both in vitro and in
vivo (Gerriets et al., 2015; Zhou et al., 2009; Almeida et al., 2016; Galgani et al., 2015).
In the highly inflammatory environments of autoimmune diseases, such as in colitis and
rheumatoid arthritis, populations of Tregs have been identified that express the Th17
master transcription factor, RORγt. Additionally, these RORγt-expressing Tregs can
produce and secrete the signature Th17 cell cytokine, IL-17 (Ren and Li, 2017).
Furthermore, both in vitro and in vivo studies showed that Th17 cells can transdifferentiate
into Foxp3-expressing T cells, in response to certain conditions, and this reprogramming
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improved disease survival in mouse-models of Th17-mediated autoimmunity. Populations
of cells have been identified that co-express Foxp3 and RORγt and that secrete IL-17,
but to a lower extent, compared to RORγt-positive T cells. (Almeida et al., 2016; Galgani
et al., 2015; Gerriets et al., 2015; Ren and Li, 2017; Zhou et al., 2009).
TGF-β is a key regulator of the observed plasticity that exists between Tregs and
Th17 cells. In response to TGF-β signaling, CD4 T cells upregulate both Foxp3 and
RORγt. The protein domain encoded by exon 2 of Foxp3 allows for its binding to RORγT.
However, when TGF-β is accompanied by signaling initiated by the proinflammatory
cytokine IL-6, Foxp3 is downregulated, allowing the induction of the Th17 program (Ren
and Li, 2017; Zhou et al., 2009).
Tregs have been shown to take on Th cell phenotypes in response to cytokine
stimulation. These signals will tune the Treg to begin expressing the Th cell signature
transcription factors and specific chemokine receptors. Some of these Tregs lose Foxp3
expression and become “exTregs”, capable of taking on pathogenic phenotypes (Raffin
et al., 2019; Scheinecker et al., 2019). There is also data suggesting Treg cells that take
on characteristics of Th cells are necessary for efficient suppression. For example,
upregulating T-bet, the Th1 signature transcription factor, has been shown to be beneficial
for Treg suppression of Th1 cells (Raffin et al., 2019; Scheinecker et al., 2019). Moreover,
Tregs that adopt Th cell phenotypes, stably express this phenotype ex vivo (Duhen et al.,
2012). However, it is unclear whether proinflammatory cytokine signaling causes Tregs
to become exTreg or to improve their suppressive capacity. It is thought that IL-2 signaling
may play a role; however, there is no conclusive data that support this hypothesis (Raffin
et al., 2019; Scheinecker et al., 2019). Furthermore, because nTregs are more
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phenotypically stable than iTregs, it has been suggested that iTregs are more susceptible
to becoming exTregs (Raffin et al., 2019).
One major difference between Tregs and Th17 cells is their differential use of
metabolic pathways. Tregs rely primarily on FAO, whereas Th17 cells are highly
glycolytic, and oxidize glutamine, as their primary energy resources (Priyaharshini et al.,
2018; Gerriets et al., 2015). Due to these distinct differences in metabolism, metabolic
regulators have been targeted to control Treg-Th17 plasticity (Ren and Li, 2017).
Numerous in vitro and in vivo studies have shown that Treg and Th17 cells can
transdifferentiate in the presence of pharmacological compounds that modulate
metabolism (Ren and Li, 2017; Mucida et al., 2007; Ozay et al., 2018; Gualdoni et al.,
2016; Wang et al., 2016; Sun et al., 2017).
1.3 Graft versus Host Disease pathology and treatment modalities
1.3.1 Failure of immunological tolerance induces autoimmunity
Immunological tolerance is defined as the ability of the immune system to
differentiate between self and non-self. There are two modes of immunological tolerance:
central and peripheral. Central tolerance occurs in the thymus. As discussed, thymocytes
are challenged with self-antigens during thymic education. This challenge ensures that
these thymocytes would not mature into self-reactive T cells. However, despite this
process, there are still some autoreactive T cells that develop. The same can occur in
maturing B cells. Although there are mechanisms to delete self-reacting B cells, some will
still enter the peripheral lymphoid tissue and secrete autoantibodies. Peripheral tolerance
is mediated by the circulating Tregs (Wang et al., 2015).
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When tolerance to self-tissue is not maintained, autoimmunity can occur, and
result in widespread inflammation and tissue destruction in the absence of pathogens.
The breach in tolerance occurs when autoreactive T cell clones slip out of the thymus. B
cells can also be autoreactive, and when not regulated properly in the bone marrow can
also slip into the periphery (Wang et al., 2015). Additionally, breach in tolerance can occur
as a result of low numbers of Tregs, Tregs that are defective, and/or Tregs that are
phenotypically unstable (Chavele and Ehrenstein, 2011). Autoimmunity is becoming more
common, affecting over 3% of the population and present with over 100 different
pathologies (Wang et al., 2015). There are several etiological factors subscribed to the
onset of autoimmune conditions, including genetic background, diet, and environmental
factors (Sharif et al., 2017). Due to the heterogeneity of these diseases, there has been
an effort to find global mechanisms that contribute to autoimmune conditions, such as
Treg insufficiencies, to identify therapeutic targets (Wang et al., 2015).
1.3.2 Graft-versus-Host Disease
Allogeneic stem cell transplantation (ASCT) is a widely used treatment that is
curative for some hematological disorders and cancers. The graft replenishes the bone
marrow with platelet, red and white blood cell progenitors, and rejuvenates thymic and
peripheral lymphoid niches. Prior to transplantation, an immunosuppressive conditioning
regimen is administered to eliminate the host’s immune cells (Moutuou et al., 2018;
Nassereddine et al., 2017). Figure 1.7 illustrates the process of ASCT. A major adverse
side effect of ASCT is the onset of Graft-versus-Host Disease (GvHD). GvHD occurs
when the donor T cells present in the stem cell graft become activated and attack the host
tissue. GvHD can develop as an acute condition within 100 days after transplant, or as a
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chronic response which occurs after 100 days post-transplant (Nassereddine et al.,
2017).
Acute GvHD is characterized by three phases: initiation, induction, and effector
phases. The initiation phase results from inflammation that occurs from the conditioning
regimen intended to suppress the host immune system. However, the conditioning can
lead to tissue destruction which initiates an inflammatory response, a cytokine storm, and
leads to the activation of host APCs. As a result, these APCs will begin to present host
antigens (self-antigens) to donor and host T cells. The APCs will present foreign MHC
proteins with self-tissue, and activation of T cells making them autoreactive
(Nassereddine et al., 2017). The induction phase is marked by T cell migration, activation,
and expansion, leading to T cell-specific cytokine release. The effector phase results from
cytokines activating cytotoxic T cells which, in turn, mediate tissue destruction (Zeiser et
al., 2016). Figure 1.8 illustrates the pathology of acute GvHD. This inflammation can be
further perpetuated by aberrations in the immune system’s intrinsic regulation.
One way in which the immune system facilitates effector cell responses is through
Treg suppression. Pro-inflammatory cytokines released during the cytokine storm can
inhibit Treg differentiation and suppressive functions, creating favorable conditions for a
pro-inflammatory T cell response (Schlöder et al., 2017). Despite prophylactic therapies,
approximately 50% of ASCT recipients will develop acute GvHD (Zeiser et al., 2016).
ASCT is still considered a frontline therapy to treat hematologic malignancies and other
immune disorders due to its curative potential. This curative potential is driven by the
Graft-versus-Leukemia (GVL) effect which results from the ability of alloreactive T cells
to destroy malignant cells (Moutuou et al., 2018). As such, a major therapeutic goal is to
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block the adverse effects of GvHD while maintaining the beneficial GVL effects after
ASCT.
1.3.3 Treatment modalities for GvHD
The host needs to be pre-conditioned prior to the graft transplant to ensure proper
engraftment of the transplant. These regimens such as radiation cause tissue damage
which elicits the cytokine storm that ultimately results in the induction of disease. There
have been efforts to deplete T cells from the graft prior to transplantation. However, this
diminishes the GVL effect, reduces engraftment potential, and can also increase other
immunological implications for the patient such as susceptibility to viral infections. The
current first-line treatment for acute GvHD is a prophylactic course of corticosteroids,
which acts as a general immunosuppressant. About half of patients with GvHD present
as steroid-refractory diminishing the survival rate to 5-30%. In addition, once GvHD
becomes steroid-refractory, there are very few non-steroid treatments currently available
to manage the tissue destruction. In recent years, mesenchymal stem cell (MSC) therapy
treatments have been investigated. There have been successes with this treatment for
some patients who present with less severe disease and primarily for those with skin
GvHD, (Nassereddine et al., 2017; Hill et al., 2018).
New, more targeted treatments for GvHD are being investigated such as
modifications to the MSC therapies and CAR-T cell therapies. CAR-T cell therapies are
very intriguing as they specifically target the alloreactive cells without inhibiting the entire
immune system. The type of CAR-T cell used for treatment differs between malignancies,
as different CAR T-cells target different surface proteins. One example of the use of CAR16

T cells in GvHD is for patients with B cell lymphomas. These patients receive lymphocyte
depleted grafts with CAR-T cells engineered in vitro from patient cells with a transgenic
receptor that recognizes CD19 on the B cells. This allows for the graft to replenish the
hematopoietic niche, prevent alloreactivity, and retain an anti-tumor response. However,
the difficulty with this approach lies in distinguishing target proteins on the malignant cell’s
membrane for the CAR-T cells to target (Smith et al., 2018).
Another non-steroidal approach is to modulate the cytokine signaling that drives
the GvHD response. Inhibiting JAK/STAT signaling has shown promising results;
however, due to the redundancy of JAK/STAT in the immune system there are off-targets
effects (Hill et al., 2018). As a result of JAK/STAT signaling, excessive amounts of
proinflammatory cytokines are produced in the extracellular milieu. These cytokines act
to drive effector T cell function while dampening iTreg function. To subdue GvHD
responses, the iTregs need to be able to suppress an inflammatory environment.
However, mainly due to IL-6 signaling, iTreg function is often inhibited. A new treatment
modality for GvHD has been to use iTreg therapy. iTregs are isolated from cord blood
and expanded ex vivo. This approach has been effective, however, expanding the iTreg
population is difficult. Additionally, it is not known how plastic these cells are in vivo. Due
to the presence of IL-6 and other proinflammatory cytokines, it is possible that these
iTregs can be converted to an effector T cell, as this phenomenon has been observed
both in vitro and in vivo. As such, more research is needed to resolve the mechanisms
behind IL-6 signaling and iTreg plasticity (Hill et al., 2018; Yurchenko et al., 2012; Chen
et al., 2009; Ramlal and Hildebrandt, 2017; Fisher et al., 2017).

17

1.3.4 iTreg therapeutic potential in GvHD
Autoimmune diseases are often treated with widespread immunosuppressive
compounds such as steroids, alkylating agents, and antimetabolites (Ferreira et al.,
2019). However, these drugs are widespread and not specific to the issue. Over the last
10 years, strategies for developing efficacious Treg therapy have been extensively
studied. Treg therapy requires the isolation of Treg cells from the peripheral blood, which
constitutes only 2-10% of blood cells, and expand them ex vivo. Alternatively, naïve CD4
T cells can be isolated from peripheral blood and differentiated in vitro and then readministered to the patient as adoptive cell therapy (Horwitz et al., 2019).
The motivation for creating Treg therapies came from GvHD studies. When the
Treg cells in the grafts were removed, the GvHD manifestation was more severe and
when Treg cells were added back into the graft, GvHD was controlled (Sharabi et al.,
2018). The first human trial of Treg therapy included two individuals who developed
GvHD: one chronic and one acute. In both patients CD4+ CD25+ CD127- T cells were
isolated from blood and expanded ex vivo, (Trzonkowski et al., 2009) in the presence of
CD3/CD28 beads and IL-2, (Trzonkowski et al., 2008). In the chronic GvHD case, the
number of CD4+ Foxp3+ cells doubled, and the patient was able to reduce steroid
therapy. Additionally, the patient’s serum proinflammatory cytokines decreased.
However, the amount of IL-10 also decreased so it is not entirely clear how efficacious
the overall therapy is in combating the disease other than the alleviation of steroid-usage.
In the acute GvHD patient, there was only minor improvement and no increase in levels
of Foxp3+ cells (Trzonkowski et al., 2009).
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Since the piloting study in 2009, there have been over 50 clinical trials for Treg
therapies registered in the US alone. Most studies have determined that Treg therapy is
safe but ineffective. It has been determined that for effective suppression the Treg
infusion should contain 106-107 Treg cells. This is difficult to achieve in vitro, so many
groups have tried to use excessive IL-2 stimulation to increase the proliferation of in
vitro-derived Treg cells. Despite the use of IL-2, the expansion capacity is variable
between donors (Ferreira et al., 2019).
In Type I diabetes, there have been successful cell transfers of Tregs that were
tracked up to two years after infusion and were found to be a safe treatment. There
were increases in the Treg expression levels of CCR7, CD38 and CD45RO all
suggesting good Treg function. However, the majority of Tregs did not last long in the
patient (Bluestone et al., 2015). In a trial of Tregs to suppress systemic lupus
erythematosus associated inflammation, the Treg survival was sustained over the 12week study. However, instead of suppressing the Th1-mediated inflammation, after the
trial the inflammation was skewed towards a Th17-phenotype (Dall’Era et al., 2019).
Interestingly, both studies demonstrated, pre-transfusion, the demethylation of the
TSDR of the Foxp3 locus of the Treg cells to be transfused to show the stability of the
population. Despite this, the Treg infusion did not show significant suppression and in
the Dall’Era trial it may have made the inflammation worse. It would be of interest to
isolate Tregs after several weeks of therapy to determine if the TSDR is still
demethylated and/or if the cells still have suppressive capacity.
One of the biggest hurdles with Treg therapy is how to stabilize the Treg phenotype
in vivo after vigorous ex vivo expansion. Several trials have determined that the Treg
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numbers are consistent after weeks of after the transfusion. However, despite the
absolute Treg numbers presented there is not significant suppression, thus these Treg
cells may develop defects in the inflammatory autoimmune environment. Several groups
have tried to increase Treg stability by blocking expression of inhibitory proteins or ectopic
expression of Foxp3 in the in vitro Treg culture, (Ferreira et al, 2019). However, it is
unclear if these techniques would stabilize the Treg cells in the face of highly inflammatory
environments.
1.4 The multifaceted roles of LKB1 in T cells
1.4.1 An overview of LKB1 biology
LKB1 is a serine/threonine kinase that was first discovered as a protein expressed
in the developing fetal liver. In 1998, LKB1 mutations were identified as a mechanism for
the development of the rare disease Peutz-Jeghers syndrome. This syndrome induces a
predisposition to sporadic tumoral growth. Interestingly, the disease-causing mutation is
a loss-of-function mutation, indicating the tumor suppressive capacity of the kinase
(Hemminki et al., 1998). LKB1 normally resides in the cytoplasm in a complex with a
pseudokinase, STRADα, and a scaffolding protein, MO25. Most kinases will be activated
by a phosphorylation of a residue in the alpha helix of the activation loop thus exposing
the kinase domain. However, LKB1 is activated by an unconventional mechanism.
Concisely, STRADα, acting as a pseudokinase, persists in a closed conformation to allow
for the interaction of MO25 and LKB1. MO25 will allow the exposure of the active
conformation of LKB1 and thus allow LKB1 to bind and phosphorylate substrates (Zeqiraj
et al., 2009).
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LKB1 is encoded by the Stk11 gene which is located on chromosome 19p. Stk11
can be alternatively spliced into three forms: long, short, and ΔN. The long form has 10
exons and a 5’ UTR, encoding a 433 amino acid protein whereas the short form has 9
exons, encoding a 404 amino acid protein in humans (Zhu et al., 2013). These are the
main isoforms that are found amongst various tissue types. Figure 1.9 illustrates the exon
and intron arrangements of these two isoforms. The ΔN form was found as a mutant that
has oncogenic properties. This isoform is spliced starting from exon 3, and found
predominantly in skeletal muscle and heart tissue (Dahmani et al., 2014; Thibert et al.,
2015).
The translated protein has a nuclear localization sequence on the N-terminus,
followed by the kinase domain. The C-terminus has modification sites for phosphorylation
and farnesylation. The short form has the entire kinase domain but has a different cterminus thus there is no farnesylation site and the phosphorylation sites differ (Zhu et
al., 2013). The ΔN form does not have the canonical N-terminus and thus does not have
a nuclear localization signal (Dahmani et al., 2014; Thibert et al., 2015). Interestingly,
despite the differences between all these forms, all three forms can take part in canonical
LKB1 signaling (Zhu et al., 2013; Dahmani et al., 2014; Thibert et al., 2015). Prior to the
activation of LKB1, the nuclear localization signal confines the protein to the nucleus
where it cannot function. The protein will be phosphorylated by Protein Kinase Cζ which
releases LKB1 from the nucleus to the cytoplasm where it interacts with downstream
targets (Zhu et al., 2013). The ΔN form does not have a nuclear localization signal nor
catalytic capacity due to an incomplete kinase domain. However, through some unknown
mechanism can activate downstream targets. This is postulated to occur through binding-
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induced conformational changes on downstream targets (Dahmani et al., 2014; Thibert
et al., 2015).
1.4.2 AMPK activation in T cells
The main substrate of LKB1 is 5’ adenosine monophosphate kinase (AMPK).
AMPK is a heterotrimeric energy sensor that allows the cell to respond to nutrient
starvation and revert to catabolic energy pathways for energy production. AMPK has
three subunits: α, β, and γ. The α subunit is the kinase domain that can phosphorylate
serine and threonine residues and the β and γ subunits bind adenylate nucleotides. When
AMP binds to the γ subunit of AMPK, the kinase is protected from dephosphorylation of
the Threonine 172 activation site and induces the kinase activity of AMPK. AMPK must
be phosphorylated on residue Threonine 172 for full activation. Interestingly, it has been
shown that during initial T cell stimulation, the associated calcium flux induces CAMKK
activation and CAMKK can activate AMPK. However, the main upstream activator of
AMPK is LKB1. Once both AMP bind and AMPK is phosphorylated at Threonine 172,
AMPK can phosphorylate downstream substrates to ensure catabolic pathways dominate
the energetics of the cell (Ma et al., 2017; Blagih et al., 2012; Lochner et al., 2015).
One way in which this occurs is through the phosphorylation of acetyl coA
carboxylase (ACC) which catalyzes the reaction of acetyl-coA to malonyl coA. MalonylcoA will drive lipid synthesis and inhibit carnitine palmoyl transferase 1 (CPT1) which is
essential for lipid oxidation. AMPK will phosphorylate ACC at serine 9 thus deactivating
it, leading to the inhibition of lipid synthesis and relieving the inhibition of lipid oxidation.
Another way in which AMPK drives catabolic energy is through the phosphorylation of the
TSC complex. When TSC1/2 are phosphorylated, it blocks the activation of mammalian
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target of rapamycin (mTOR) which engages the cell in processes such as protein
synthesis and glycolysis. Figure 1.10 illustrates some of the ways in which the
LKB1/AMPK pathway can regulate cellular energetics towards catabolic processes (Ma
et al., 2017; Blagih et al., 2012; Lochner et al., 2015).
1.4.3 LKB1 in effector T cells
The role of AMPK in mature peripheral T cells, has been studied extensively (Ma
et al., 2017). However, several studies over the past decade have demonstrated that
there are AMPK-independent functions of LKB1 in T cells. One of these functions is that
LKB1 regulates the survival and proliferation of T cells. Upon activation, T cells will
undergo rapid proliferation; however, if LKB1 is conditionally ablated, this proliferation is
obstructed, irrespective of the addition of CD28 (MacIver et al., 2011; Tamás et al., 2010).
Additionally, T cells lacking LKB1 have survival deficiencies, presumably from inadequacy
of the energy demands put forth by rapid proliferation. This is presumably because these
cells expressed higher amounts of Bax, a proapoptotic BCL-2 family protein, then wild
type cells upon metabolic stress. However, this survival defect can be circumvented by
transgenic expression of BcL-xL (MacIver et al., 2011).
Unsurprisingly, LKB1 also has an impact on T cell metabolism. LKB1 -/- T cells
have increased glycolytic rates and elevated expression of glycolytic enzymes.
Additionally, in the absence of LKB1, the uptake of glucose is increased due to increased
expression of the glucose transporter, GLUT1. Regarding effector function, LKB1 -/- T cells
show increased activation as evidenced by CD44 expression and greater cytokine
production. When LKB1-/- CD4 T cells were polarized in vitro towards a Th1, Th2, or Th17
phenotype, all subsets showed increased cytokine production as compared to WT. This
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phenomenon seems to be unique to LKB1, as AMPK-/- CD4 T cells did not show
increased cytokine production. CD8 T cells that were activated in the absence of LKB1,
also showed increased cytokine production of IL-17A and IFN however this effect was
mirrored in AMPK deficient CD8 T cells Interestingly, the increased levels of IFN in both
the LKB1-/- and AMPK-/- CD8 cells was diminished upon addition of rapamycin,
suggesting that the increased IFN expression is due to the increased mTORC1 induced
by deficiency of either LKB1 or AMPK (MacIver et al., 2011).
1.4.4 LKB1 in regulatory T cells
LKB1 has been extensively studied as a metabolic regulator in times of cellular
stress. Treg cells exhibit a metabolic phenotype that is analogous to cellular starvation
with the increased usage of autophagy and fatty acid oxidation, as compared to effector
T cells. As such, over the past several years the role of LKB1 in Treg cells has become
of interest. Several studies have shown that ablation of LKB1 in Tregs induces
widespread autoimmunity and interestingly, the effect on Treg cells are AMPKindependent. It has been suggested that the effect of LKB1 on Treg cells may be mediated
by other kinases downstream of LKB1 such as MAP/mitochondrial affinity-regulating
kinases (MARKs) and salt-inducible kinases (SIK; He et al., 2017).
The first study to evaluate the contribution of LKB1 in the Treg phenotype
examined the relationship between Foxp3 and LKB1. This study demonstrated that LKB1
is highly expressed in Treg cells as compared to conventionally stimulated CD4 T cells.
Furthermore, this study presented evidence that LKB1 stabilizes Foxp3 expression by
blocking STAT4 which methylates CNS2 on the Foxp3 locus (Wu et al., 2017). The

24

specific role of LKB1 in the inhibition of CNS2 methylation was also shown in human Treg
cells from patients with acute GvHD. These patients had lower frequencies of Treg cells
and the Treg cells were highly unstable as the CNS2 region was demethylated compared
to healthy controls (Su et al., 2019). LKB1 has been shown to contribute to TGF-
signaling as LKB1 floxed Tregs have reduced TGF- signaling due to the lower
expression of TGF- receptors (Wu et al., 2017).
LKB1 also reduces co-receptors OX-40, PD-1, and GITR expression on Treg cells
to inhibit type 2 inflammation. This modification occurs through modulation of -catenin
activity thus leading to widespread inflammation (Yang et al., 2017). Interestingly, LKB1deficiency in dendritic cells allows for increased Treg proliferation. This occurs through
increased expression of OX-40 ligand on the dendritic cells in the absence of LKB1
leading to increased proliferation which is attributed to more contact between the Treg
and dendritic cells. Further, the authors demonstrated that LPS or bacterial stimulation of
dendritic cells led to the complete abrogation of LKB1 in dendritic cells. This suggests
that LKB1 may act as a rheostat of Treg activity during infection (Chen et al., 2018).
As expected, LKB1 deficiency reduces the rates of fatty acid oxidation in Treg cells.
Furthermore, LKB1-deficient Treg cells show overall perturbation in the mitochondria as
evidenced by lower mitochondrial mass, less reactive oxygen species, lower
mitochondrial membrane potential, and defects in oxidative phosphorylation. All of this
leads to the reduced quantity of intracellular ATP in the cells. This is presumably one of
the reasons for the low survival rates of Treg cells in the absence of LKB1 (He et al.,
2017; Yang et al., 2017). Additionally, LKB1-deficient Treg cells demonstrate reduced
activity of the mevalonate pathway which lead to reduced expression of Foxp3 and
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subsequently less suppressive capacity. Interestingly, LKB1-deficency and subsequent
aberration of the mevalonate pathway led to the Tregs expressing IFN and IL-17A,
suggesting phenotypic instability (Timilshina et al., 2019).
1.5 PKCθ in T cell signaling
1.5.1 PKCθ in T cell activation
Protein kinase Cθ (PKCθ) is a T-cell specific kinase that functions in T cell
activation and induction of effector function. PKCθ is serine/threonine kinase from the
Ca++- independent Protein Kinase C family, which is activated by diacylglycerol (Isakov
and Altman, 2002). T cell signaling induces the hydrolysis of phospholipase C to
diacylglycerol, which binds to the C1 domain of PKCθ and tethers the protein to the
immunological synapse created between the T cell and APC. Recruitment of PKCθ to the
immunological synapse allows for the interaction between PKCθ and LCK and LCK acts
as a bridge PKCθ and CD28 (Brezar et al., 2015).
PKCθ regulates the activity of NF-kB upon T cell activation which culminates in IL2 production. NF-κB transcription factors are sequestered in the cytoplasm by IκB
phosphorylation. T cells have the CARMA1-BCL10-MALT1 (CBM) complex that has the
capacity to ignite the signaling pathway to release NF-kB. After PKCθ is recruited to the
immunological synapse it will phosphorylate CARMA1 which will allow for the formation
of the CBM complex. MALT1 will activate the IκB complex (IKK) and lead to the
degradation of IκB and the release of NF-κB transcription factors from the cytoplasm
(Isakov and Altman, 2002; Lucas et al., 2004; Brezar et al., 2015).

26

PKC also has a direct role in gene expression in T cells. Sutcliffe et al., 2011
showed for the first time that PKC is catalytically active in the nucleus as well as in the
cytoplasm in activated T cells. PKC binds to active chromatin and forms a transcriptional
complex with RNA polymerase II, histone kinase mitogen and stress activated kinase-1
(MSK-1), 14-3-3, and lysine specific demethylase 1 (LSD1). This complex binds to
promoters of T cell activation genes such as cd69 and microRNAs to modulate T cell
function (Sutcliffe et al., 2011; Sutcliffe and Rao, 2011).
1.5.2 PKCθ has opposing functions in effector and regulatory T cells
PKC is crucial for Th17 cell differentiation as PKC-/- T cells exhibit a diminished
Th17 phenotype. There are several Th17 differentiation mechanisms that require PKC
function. IL-6 signaling is necessary for Th17 differentiation. Downstream of IL-6, STAT3
is activated and induces the upregulation of RORt and IL-17. PKC has been shown to
regulate Stat3 expression, (Kwon et al., 2013). Furthermore, PKC activates sterol
regulatory complex 1 (SRC1) which regulates the transcription of Rorc, the transcript for
RORt. As such, PKC is crucial for Th17 cell differentiation and effector function, through
modulation of IL-17 production (Sen et al., 2018).
In Tregs, PKC has been shown to have an inhibitory role. PKC-/- mice exhibit
increased Treg number in vivo, and an increased capacity for in vitro Treg differentiation.
PKC signaling modulates the activity of the AKT pathway. In the absence of PKC, AKT
phosphorylates transcription factors Foxo1/3a which drives Foxp3 upregulation (Ma et al.,
2012). PKC also affects the suppressive capacity of Treg cells. PKC is sequestered
away from the immunological synapse in Treg cells to prevent Tumor necrosis factor27

alpha (TNF-) production. This has been shown to prevent the Treg from undergoing
TNF- mediated inactivation of the Treg. Furthermore, in autoimmune models, if PKC is
inhibited on the Treg cells, the Treg cells are more efficacious in suppression in the proinflammatory autoimmune environment (Zanin-Zhorov et al., 2010).
1.6 RNA processing
1.6.1 RNA splicing
Upon transcription by RNA polymerase II, immature messenger RNA (mRNA)
transcripts will undergo a variety of modifications during RNA maturation. Maturation of
the RNA allows for its export from the nucleus to the cytoplasm to the ribosome for
translation. Three major modifications occur during the maturation process: 5’ capping, 3’
polyadenylation, and splicing (Bentley, 2014). The 5’ cap and 3’ polyadenylation protect
the transcript, allow for nuclear export, and aid in the translation process. The mature
RNA will also require non-coding introns to be spliced out of the transcript to allow for the
coding exons to be ligated together. In addition to the basic splicing out of introns,
alternative splicing can occur. Normally, constitutive splicing will ligate exons in the linear
sequence in which they appear. However, alternative splicing confers great diversity of
potential gene products by allowing for exons in different regions of the transcript to be
ligated together. Even more diversity can be introduced by changing the established
intron boundaries in the transcript. These measures allow for the possibility of drastically
different versions, or isoforms, of the same transcript (Black et al., 2019).
RNA splicing is a highly regulated and complex process that requires the formation
of the spliceosome, a multiprotein complex that recognizes splicing sites and induces
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splicing of the transcript. The spliceosome contains five small nuclear ribonucleoproteins
(snRNPs) U1, U2, U4, U5, and U6, which work in unison to accurately identify splice sites
on the transcript. U1 is the first component to bind and binds at the 5’ splice site. The U2
auxiliary factor (U2AF) heterodimer will then recognize and bind to the 3’ splice site (Black
et al., 2019). The heterodimer is made up of the U2AF35 and U2A65 subunits which bind,
respectively, to pyrimidine stretches and the AG dinucleotide found at the junction of the
intron and exon (Shenasa and Hertel, 2019). The U2AF heterodimer recruits and aids in
the incorporation of the U2 unit. The U2 unit will bind by base pairing with the branch point
site. Subsequently the U4.U6/U5 tri-snRNPs are recruited into the splice site. The
proteins in this complex will act to drive a transesterification reaction to ligate the exons
and release the intron. Figure 1.11 depicts the overall splicing reaction (Black et al., 2019).
1.6.2 RNA binding proteins
Alternative splicing occurs in over 90% of the human genome conferring the great
diversity seen within the human proteome. Interestingly, the different isoforms generated
from a single gene tend to be expressed in a tissue-specific fashion and are regulated by
the splicing code. Within the splicing code are cis and trans acting elements that modulate
the strength of the splice site and the resulting splice variant (Neil and Fairbrother, 2019).
Alternative splice sites are usually weak but can be significantly enhanced by
trans-acting elements, RNA binding proteins (RBPs). To enhance splicing, the RBP binds
to the cis-element, the intron splicing enhancer (ISE), or the exon splicing enhancer (ESE)
which is located within the material to be spliced out. The RBP acts as a flag, promoting
splicesome complex formation on the site and stabilizing the interaction. Conversely, RBP
binding to the intron splicing silencer (ISS) or exon splicing silencer (ESS), acts to inhibit
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splicesome binding to the splice site (Black et al., 2019). A schematic of this process is
found in Figure 1.12. There are two main families of RBPs: serine and arginine-rich (SR)
proteins and heterogenous nuclear ribonucleoproteins (hnRNP). SR proteins tend to
associate more with enhancers while hnRNP proteins associate more frequently with
silencers. However, it has been demonstrated that both proteins can bind enhancers or
silencers, both, making the splicing code much more nuanced than originally thought
(House and Lynch 2008).
1.6.3 HnRNP proteins in T cell activation and function
There are 20 major members in the hnRNP protein family. These proteins can
affect transcription by modulating transcript expression, stability, and transport. The
hnRNP proteins have a nuclear localization signal and reside primarily in the nucleus.
However, some hnRNPs also have a cytoplasmic function regulated by post-translational
modifications or recruitment by other proteins which allow translocation of the hnRNP
from the nucleus to the cytoplasm. There are four RNA-binding motifs common to the
hnRNP family: the KH domain, the RNA recognition motif (RRM), the quasi-RRM, and the
arginine-glycine-glycine (RGG) motif. Although there is redundancy in the RNA binding
sequences, diversity is conferred by additional auxiliary domains and post-translation
domains (Geuens et al, 2016).
There are many genes that are alternatively spliced in T cells. These include genes
encoding cytokines, cytokine receptors, kinases, transmembrane receptors, and
intracellular signaling proteins. Differences in stimuli, cell phenotype, or even malignant
transformation can all drive differential splicing of these genes. The canonical example of
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hnRNP-mediated splicing effects on T cell activation is through the splicing of CD45
(Lynch, 2004).
CD45 is a transmembrane protein tyrosine phosphatase that is encoded by the
gene Prprc (Holmes, 2006). CD45 function is crucial to T cell activation because it
dephosphorylates the inhibitory Y505 phosphorylation of LCK, allowing for the
subsequent activation signaling cascades to ensue (Zamoyska, 2007). CD45 is
alternatively spliced into 5 different protein-coding variants that result from splicing of
exons 4-6 and produce isoforms with different extracellular domains. Different isoforms
are expressed in different cell phenotypes and correspond with the cells’ maturity and
activation status. In naïve peripheral T cells, the CD45RA isoform is expressed. As the
cell becomes activated it will produce the CD45RO isoform, which lacks exons 4-6.
Additionally, memory T cells are also characterized by the expression of CD45RO.
CD45RO is considerably smaller than CD45RA and, as such, allows the CD45 proteins
to dimerize more easily. Once dimerized, the phosphatase ability is sterically inhibited,
acting as a feedback loop to curtail excessive activation of the cell (Lynch 2004).
CD45 splicing is regulated by hnRNPL and hnRNPLL. However, hnRNPLL is
upregulated by CD28 engagement and is thought to more directly control T cell activationmediated CD45 splicing (Butte et al., 2012; Oberdoerffer et al., 2008). To generate
CD45RO, hnRNPLL binds to exons 4 and 6 at the respective ESS. When hnRNPLL is
bound to both exons, it forms a stable complex due to cross-exon interaction and allows
for exon 5 to be included in the lariat that is spliced out of the transcript. HnRNPL can
also bind exon 4 but cannot bind exon 5 or 6 thus hnRNPL, alone, is unable to generate
the CD45RO isoform (Preuner et al., 2012; Figure 1.13).
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In addition to regulating CD45, hnRNPLL has been shown to be a global splicing
regulator in activated T cells. HnRNPLL expression and the number of spliced transcripts,
both, are increased following CD28 engagement. There are several other genes that are
targets of hnRNPLL that have been identified that could affect T cell differentiation and
function, such as CD44, STAT5a, and fatty acid synthase (Butte et al., 2012).
1.7 Rationale and hypothesis
Naïve T cells circulate through peripheral lymphoid tissues until they encounter
antigen in the context of peptide:MHC presented by an APC. The T cell will receive two
signals from surface receptors on the APC, and a third signal from cytokines in the
microenvironment, to fully engage the T cell activation program. Initially, IL-2 signaling
through autocrine and paracrine networks, is necessary for full T cell activation and
proliferation. Additional cytokine signals will induce the cell to differentiate into specific
effector states. APCs secrete different cytokines, depending on the nature of the
engulfed antigen, to prime the T cell to specifically target this type of pathogen. The
cytokine signal will drive upregulation of a signature transcription factor in the T cell,
which will further induce acquisition of effector function, mainly through effector cell
cytokine production (Zhou et al., 2009).
It was originally thought that T cell differentiation is an irreversible phenomenon,
but several studies have demonstrated that T cells can reacquire the signature identity
of a different effector phenotype, through a process known as plasticity. Plasticity can
occur between several different T cell subsets but is observed most markedly between
iTreg and Th17 cells (Zhou et al., 2009). TGF- signaling is crucial in the differentiation
of both subsets through its upregulation of Foxp3 and RORt, both. Foxp3 associates
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with the DNA binding domain of RORt, to render RORt incapable of modulating gene
expression, thus allowing Foxp3 to drive a suppressive program (Zhou et al., 2008). In
the presence of TGF- together with the pro-inflammatory cytokine IL-6, Foxp3
becomes acetylated which alters its ability to bind to target genes, and thus allows
RORt to translocate to the nucleus and activate the Th17 differentiation program
(Samanta et al., 2008).
In some autoimmune diseases, such as in psoriasis and rheumatoid arthritis,
iTregs can take on Th17 functions, such as IL-17 production, in vivo, especially in the
context of a highly inflammatory environment. However, it is not clear whether these
Tregs retain their suppressive capacity and this ability may, in fact, be disease specific.
For example, in colitis models, populations of FOXP3+ RORT+ Tregs were identified
that retained their suppressive capacity, whereas Th17-producing Tregs enhanced the
inflammatory pathology seen in psoriasis. In vitro, iTregs can be reprogrammed to adopt
a Th17 phenotype in the presence of Th17-inducing cytokines, such as IL-6 (Ren and Li,
2017). However, the question remains how these signals are integrated and how they
affect immunological tolerance.
An emerging regulator of the balance between effector T cells and regulatory T
cells is PKC. Treg cells receive negative feedback from TCR/CD28 signaling and
resultant PKC and AKT activation. However, Treg cells also need to build an
immunological synapse with an APC for proper activation (Zanin-Zhorov et al., 2010). In
effector T cells, TCR/CD28 signaling induces PKC to translocate within lipid rafts to form
the central region of the immunological synapse (IS) which is formed upon TCR:APC
interaction. IS recruitment brings PKC into close proximity with its substrate, CARMA1,
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and ultimately leads to the liberation and translocation of NF-B transcription factors to
the nucleus where they mediate gene expression (Brezar et al., 2015). However, in Treg
cells, PKC is not recruited to the immunological synapse, thus protecting Tregs from
TCR-mediated inactivation and from TNF--mediated inhibition of suppressive activity.
Inhibiting PKC activity also preserves Foxp3 expression (Zanin-Zhorov et al., 2010).
In contrast, PKC is essential for Th17 cell differentiation and effector function.
PKC-deficient Th17 cells express less RORt and secrete less IL-17. PKC has several
effects on Th17 phenotype acquisition. PKC in coordination with NF-B and AP-1,
stimulates the expression of STAT3, an adaptor molecule which transmits signals through
the IL-6 receptor (Kwon et al., 2012). Additionally, PKC phosphorylates steroid receptor
coactivator (SRC) which, when phosphorylated, mediates RORt-DNA binding and drives
IL-17 production. Phosphorylated SRC also drives Foxp3 degradation, relieving Foxp3mediated inhibition of RORt (Sen et al., 2017).
How changes in the metabolic profiles may affect the plasticity of different cell
subsets represents another area of active inquiry. Naïve CD4 T cells are metabolically
quiescent and rely on oxidative phosphorylation as their primary means of generating
cellular energy (Chapman et al., 2019). Following activation, effector T cells undergo
metabolic changes to accommodate the increased energy demands that accompany
proliferation effector functions. TCR and CD28 engagement upregulate glycolytic
pathways, including the mTORC1 pathway, to facilitate increased glucose transport. In
contrast, Treg cells utilize fatty acid oxidation and oxidative phosphorylation to derive
energy and can thrive in environments where glucose availability is low (Blagih et al.,
2012; Gerriets et al., 2015). It is curious that there exists such a high level of plasticity
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between two cell types that utilize markedly different metabolic profiles. In recent years,
our group and others have shown that T helper cell phenotype can be changed by
pharmacologically manipulating cellular metabolism. However, a clear mechanism
describing how these metabolic switches occur, and whether they drive, or result from,
changes in Treg-Th17 cell plasticity has yet to be fully elucidated.
Liver Kinase B1 (LKB1) is a metabolic regulator that drives energy processes like
FAO. As Tregs preferentially metabolize fatty acids, the role of LKB1 in Treg biology has
become of interest. Over the past several years, different studies have been shown that
LKB1 protects Treg function by maintaining metabolism, cellular survival, and Foxp3
expression (He et al., 2017; Timilshina et al., 2019; Wu et al., 2017; Yang et al., 2017).
In acute GvHD patients, their Tregs had very low levels of LKB1 which correlated with
low Foxp3 expression, suggesting a role of LKB1 in the maintenance of peripheral
tolerance (Su et al., 2019). In addition, when LKB1 was deleted from Tregs in vivo,
these cells started expressing pro-inflammatory cytokines (Timilshina et al., 2019). This
suggests that LKB1 regulates phenotypic stability. However, is this through the effect on
Foxp3 or does LKB1 have an intrinsic effect on stability?
These pieces of data suggest that LKB1 is crucial to Treg identity in regard to
Foxp3 expression and resultant suppressive capacity. However, is this a result of Foxp3
expression itself or does LKB1 have an intrinsic effect on phenotypic stability. In this
study, our central hypothesis is that LKB1 regulates the plasticity axis between Th17
cells and iTregs.

35

Figure 1.1 T cell activation
T cells require three signals for complete activation and the induction of
proliferative and survival pathways. Signal 1 is mediated through the TCR and
MHC association. Signal 2 is mediated through CD28 and CD80/86. Signal 3 is
mediated through cytokine signals.
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Figure 1.2 JAK/STAT signaling
Cytokines bind a specific receptor to illicit a cellular response. JAK kinases
are bound to the cytokine receptor and become autophosphorylated when
ligand binds the receptor. Activated JAK phosphorylates STAT protein,
exposing a Sh2 domain which allows STAT proteins to dimerize. STAT
dimers can enter the nucleus and modulate gene expression. Adapted from
Dodington et al., 2018.
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Figure 1.3 CD4 helper T cell subsets
A naïve CD4 T cell will receive cytokine signaling from the APC that has
activated it. The specific cytokine signals will upregulate the signature
transcription factor of the effector subset. The signature transcription factor
will induce the production and secretion of cytokines that are most
efficacious at targeting the specific pathogen.
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Figure 1.4 nTreg differentiation
Single-positive CD4 thymocytes are challenged with self-antigens
produced by Aire expression, in orange. If the thymocyte reacts strongly
to the self-antigen it will undergo apoptosis. Whereas if the thymocyte
reacts moderately to the self-antigen, it will upregulate CD25 and
Foxp3, and exit to the periphery until it is activated. Modified from Kuby
th
Immunology, 7 edition
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Figure 1.5 Cellular energy production
Different metabolic pathways can be used to generate acetyl-coA and
TCA intermediates to fuel the TCA cycle. The TCA cycle will reduce
electron carriers to be used in OXPHOS and result in ATP production.
Adapted from Galgani et al., 2015.
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Figure 1.6 The Warburg effect
Upon activation, T cells will undergo the Warburg Effect which induces
the cell to undergo glycolysis and convert glucose into lactate under
normal oxygen conditions. The lactate production produces NAD+ which
will be used for OXPHOS to produce ATP. Adapted from Fox et al., 2005.

41

Figure 1.7 ASCT and the onset of GvHD
ASCT is a curative treatment for hematological disorders and cancers.
The recipient undergoes a conditioning regimen to deplete the recipient’s
immune cells. The recipient will then receive a transfusion of the donor
cells. The donor cells will kill any remaining cancer cells. However, the
donor cells can also attack the recipient’s tissue, the manifestation of
GvHD. Adapted from Shono and van den Brink, 2018.
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Figure 1.8 The pathology of GvHD
(1) Initiation of GvHD is caused by the pre-conditioning regimen. (2) The
conditioning regimen induces a cytokine storm and activates cells in the
graft. (3) The activated donor cells will cause tissue damage by reacting to
self-antigens and killing recipient cells. Adapted from Ferrara and Levine,
2008.
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Figure 1.9 The main isoforms of Stk11
Stk11 is the gene that encodes for LKB1. There are two main isoforms,
long and short. The short isoform is encoded by exon 9a and has a stop
codon at the end of the exon, changing the 3’UTR of the transcript. The
short form has the entire kinase domain but loses the farnesylation site
and has a different phosphorylation site.
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Figure 1.10 The LKB1/AMPK pathway regulates cellular energetics
LKB1 phosphorylates and activates AMPK. AMPK can phosphorylate
numerous substrates, all working towards driving the cell towards
catabolic energy processes. A few of the substrates of AMPK are
illustrated in this figure.
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Figure 1.11 Formation of the spliceosome
The spliceosome is a multiprotein complex that recognizes and binds to
the splice sites on a transcript. U1 binds to the 5’ splice site first. This
allows for U2AF to bind to the 3’ splice site and recruit U2 to base pair at
the branch point site. Once U2 is bound, the U4.U6/U5 tri-snRNPs can
bind, induce the transesterification reaction which will release the introns
and ligate the exons. Adapted from House and Lynch, 2007.
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Figure 1.12 RBPs regulate spliceosome formation
RBPs can orchestrate the splicing of a transcript by binding enhancer
regions and recruit the spliceosome to bind to the transcript. Conversely,
RBPs can block spliceosome recruitment by binding silencer regions and
block the spliceosome from binding to the transcript. Adapted from Black
et al., 2019.
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Figure 1.13 HnRNPLL and hnRNPL regulate CD45 splicing
HnRNPLL can bind to exons 4 and 6 to induce the splicing of exons 4-6.
However, hnRNPL can only bind to exon 4. Thus, hnRNPL alone cannot
generate the isoform CD45RO. Modified from Preuner et al., 2012.
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CHAPTER 2
LKB1 SPLICING IS MEDIATED THROUGH HNRNPLL AND PKC Signaling

2.1 Introduction
LKB1 is an essential energy regulator of Treg metabolism (He et al. 2017). As
such, we hypothesized that iTreg cells, which mainly utilize fatty acid oxidation for
energy, would express more LKB1 compared to Th17 cells, which are highly glycolytic.
LKB1 phosphorylates and activates AMPK to perpetuate FAO by subsequently
activating CPT1a, a fatty acid oxidation enzyme, and blocking ACC, a FAS enzyme,
refer to Figure 1.10 (Lochner et al., 2015; Ma et al., 2017). LKB1 has numerous
functions in Treg cells, with the most important being maintaining Foxp3 expression.
Stable Foxp3 expression has been shown to be LKB1-dependent through its inhibitory
effects on CNS methylation. Furthermore, LKB1 ablation correlates with loss of Foxp3
expression. Whether this is achieved by maintaining open chromatin, through increased
protein stability, or both, has yet to be established (He et al., 2017; Wu et al., 2017;
Yang et al., 2017). However, to our knowledge, no one has yet explored how LKB1 may
contribute to iTreg-Th17 plasticity. To this end, we hypothesized that LKB1 would not
be expressed in Th17 cells and that expression of LKB1 would maintain the Treg
phenotype.
2.2 Results
2.2.1 LKB1 is expressed in both Th17 and iTreg cells
To determine if LKB1 expression differs between iTreg and Th17 cells, we
needed to develop a protocol that would provide a homogenous and stable cell
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population. Primary CD4+ T cells were negatively selected prior to differentiation in
vitro. We used RORt+ expression to define Th17 cells and CD25+ Foxp3+ expression
to identify iTregs, Figure 2.1. We did not assess CD4 expression, as these cells were
negatively selected for CD4 expression prior to stimulation and differentiation. To verify
that this Treg population was indeed functional, we assessed the presence of nuclear
Foxp3, Figure 2.1. We determined that the optimal culturing of naive splenic CD4 T cells
to differentiate was over a period of 7 days.
To assess LKB1 expression within the two subsets, we first gated cells on RORt
or Foxp3 expression within Th17 or iTreg cells, respectively, and then measured LKB1
levels via flow cytometry. As a control, we stimulated naïve CD4 T cells in the presence
of IL-2. These cells are considered stimulated but non-polarized (NP). We found that
greater than 90% of Th17 cells and iTregs, both, expressed LKB1. Surprisingly, Th17
cells expressed approximately three times more LKB1 than did iTregs or NP cells, as
determined by median fluorescence intensity (MFI), a readout of relative protein
expression, Figure 2.2.
LKB1 is activated in the cytoplasm through its association with STRAD and
MO25 proteins (Zeqiraj et al., 2009). Prior to its activation, LKB1 resides in the nucleus
until phosphorylated by PKC, which frees LKB1 from its nuclear constraints (Zhu et al.,
2013). We questioned whether, although the Th17 cells expressed more LKB1 than
iTregs, was it perhaps retained in the nucleus and thus, not activated? Using AMNIS
imaging flow cytometry, we asked whether Th17 cells had more nuclear LKB1 than
iTreg cells. Using the IDEAS software and the nuclear similarity algorithm, we
determined that there was not a significant difference in the nuclear residency of LKB1
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between subsets. We made this determination by analyzing the percent of cells in the
population staining positive for nuclear LKB1 together with the nuclear similarity score,
Figure 2.2. Although we did not fully confirm the activation status of the protein, it has
been demonstrated by others that activated LKB1 resides in the cytoplasm. Since we
saw no differences in nuclear LKB1, we presumed that the amount of activated LKB1
may be similar between Th17 and iTreg cells.
2.2.2 LKB1 Isoforms are differentially expressed in Th17 and iTreg cells
LKB1 can exist as one of 2 splice variants: a short (LKB1S) or a long (LKB1L)
isoform. LKB1 is encoded by the gene, Stk11, which is comprised of 9 exons and a 3’
UTR. There are two versions of exon 9, 9a and 9b, with exon 9a only expressed in the
short isoform of LKB1. Exon 9a contains a stop codon, leading to a truncated transcript
(LKB1S) with no 3’UTR. Exon 9a is a cryptic exon that is spliced from intron 8, Figure
2.3. Given that LKB1 can exist in different forms, we revised our hypothesis to ask
whether Th17 cells and iTregs express different isoforms of LKB1. We designed primers
to specifically amplify exon 9a in Stk11S, exon 9b in Stk11L, as well as to exon 1 which
is expressed in both Stk11S and Stk11L, and which we refer to as the “common” exon,
Figure 2.3. Using qRT-PCR, we determined that Th17 cells express approximately 2fold more Stk11S than iTregs, Figure 2.4. The ratio of Stk11S:Stk11L was significantly
higher in Th17 cells, compared to iTregs, indicating that Stk11S is the predominant form
of LKB1 in Th17 cells, Figure 2.4. We also confirmed, by immunoblot, that LKB1S is
more abundantly expressed in Th17 cells than in iTregs, Figure 2.4. Altogether, our data
show that Th17 cells express higher levels of LKB1 than do iTregs. Furthermore, Th17
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cells and iTregs express different splice variants of Stk11, with Th17 cells expressing
significantly more Stk11S/LKB1S than iTregs.
2.2.3 HnRNPLL associates with the short Stk11 isoform
RNA binding proteins (RBPs) help guide components of the spliceosome to
newly synthesized transcripts to mediate splicing events (Lynch, 2004). RBPmap is a
tool that predicts binding sites on transcripts by RNA binding proteins by identifying
binding motifs within transcript sequences (Paz et al., 2014). We analyzed the Stk11
sequence using RBPmap scan, and identified heterogenous nuclear ribonucleotide
protein L-like (hnRNPLL) as one of the RBPs that showed strong binding potential.
HnRNPLL seemed like a good target to explore since it has already been shown to
have a role in CD45 splicing in T cells (Wu et al., 2008). Therefore, we asked whether
hnRNPLL might also have a function in Stk11 splicing. We measured the expression of
hnRNPLL in Th17 cells and iTregs. We found that Th17 cells express more hnRNPLL
than iTregs, Figure 2.5. We next asked whether differences in hnRNPLL expression has
functional consequences for Stk11 splicing in Th17 and iTreg cells. We generated
whole cell lysates from Th17 and iTreg cells, in which RBPs were bound to RNA
through a cross-linking step. We then immunoprecipitated hnRNPLL from the cell
lysates to enrich for RNA transcripts that were bound to hnRNPLL. We used the Stk11s
primer set to determine whether Stk11s was preferentially associated with hnRNPLL in
Th17 cells as compared to iTreg cells. As shown in Figure 2.5, we observed that, in
Th17 cells there was significantly more Stk11s transcript bound to hnRNPLL, than in
iTregs.
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We previously showed we can restrict the function of a target protein using a
specific antibody complexed to a synthetic peptide containing a protein transduction
domain mimic (PTDM) which will transport it across the cell membrane (Ozay et al.,
2016). HnRNPLL was shown to mediate alternative splicing of CD45 in activated in T
cells (Wu et al., 2008); therefore, we assessed CD45 splicing as a readout of effective
delivery of anti-hnRNPLL. Consistent with previous results, when we delivered an
antibody to hnRNPLL into CD4 T cells, we found that anti-hnRNPLL treatment altered
the expression of CD45 isoforms (Figure 2.6). To further explore how hnRNPLL
mediates Stk11 alternative splicing, we delivered anti-hnRNPLL into CD4 T cells, then
assessed Stk11 transcript expression after Th17 polarization. Interestingly, we found a
large increase in the level of the Stk11 common transcript, Figure 2.6, perhaps as a
compensatory mechanism. However, when we measured the level Stk11s relative to
that of the common transcript, we found that anti-hnRNPLL delivery significantly
reduced Stk11s expression and the ratio of Stk11S:Stk11L in Th17 cells, Figure 2.6.
These data confirm that functional hnRNPLL is required for efficient Stk11 alternative
splicing in Th17 cells, and by using a cell penetrating peptide to deliver anti-hnRNPLL in
CD4 T cells prior to Th17 differentiation we can modulate the alternative splicing
process that generates Stk11s.
2.2.4 PKC regulates hnRNPLL expression and Stk11s splicing in Th17 cells
PKCθ functions downstream of CD28 signaling and has been shown to be
necessary for Th17 differentiation, while also acting to inhibit iTreg function (Ma et al.,
2012; Sen et al., 2018; Kwon et al., 2012). Additionally, PKCθ has been shown to
regulate the splicing activity of RBPs, such as that of SC-35 (McCuaig et al., 2015).
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Interestingly, hnRNPLL protein expression is also upregulated following CD28
engagement (Butte et al., 2012). Therefore, we asked whether PKCθ regulates
hnRNPLL-mediated LKB1s expression in Th17 cells. Compared to iTregs, there was
significantly more Prkcq, the transcript that encodes PKCθ, in Th17 cells, Figure 2.7.
Furthermore, when naive CD4 T cells from PKCθ-/- mice are stimulated and cultured
under Th17 polarizing conditions, they show defective Th17 differentiation, as
characterized by diminished Il17f production, the Th17 master effector cytokine, Figure
2.7. In Th17 cells that lack PKCθ, Hnrnpll transcript expression is abrogated, whereas in
Th17 cells that express WT PKCθ, we observed robust levels of Hnrnpll, confirming
PKCθ is necessary for Hnrnpll expression in Th17 cells, Figure 2.7.
We demonstrated that hnRNPLL functions to regulate Stk11 alternative splicing,
Figure 2.6. Therefore, we hypothesized that, in PKCθ-/- Th17 cells, we would observe
defective Stk11 splicing. We found that, compared to WT Th17 cells, there is
significantly less Stk11S in Th17 cells lacking PKCθ, Figure 2.7. These data suggest that
PKCθ regulates hnRNPLL expression in Th17 cells, which further functions to mediate
Stk11 alternative splicing.
2.2.5 Inhibiting PKC alters hnRNPLL and LKB1 expression in iTregs
We determined that PKC is important for inducing hnRNPLL expression in Th17
cells. Therefore, we hypothesized that deleting PKC would reduce the expression of
hnRNPLL in iTregs. To test this, we differentiated WT and PKC-/- CD4 T cells into iTreg
cells. We evaluated hnRNPLL expression via immunoblot and observed a slight
reduction in the amount of protein expressed, Figure 2.8. This led us to further
investigate the expression of LKB1S expressed in PKC-/- iTregs. We observed a
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reduction in LKB1S, in iTregs that lack PKC Figure 2.8. Although these data did not
meet statistical significance, it demonstrates PKC does regulate LKB1 alternative
splicing, but that there are other signals involved in this pathway.
2.3 Discussion
LKB1 is emerging as an important regulator of Treg function and survival through
mechanisms that act through STATs, -catenin, and microtubule-affinity regulating
kinase signaling (He et al., 2017; Wu et al., 2017; Yang et al., 2017). These are in
addition to AMPK-dependent LKB1 activities which facilitate fatty acid oxidation and
autophagic processes in Tregs. However, whether or if LKB1 functions in Th17 cell
differentiation has not been explored previously. We identified a significant increase in
LKB1 expression in Th17 cells polarized in vitro, compared to iTregs. Further, we
presume that the activation of LKB1 is similar between both subsets as we observed
that there was no significant difference in the number of cells that express nuclear LKB1
between both subsets. Intriguingly, we determined that Stk11, which encodes LKB1,
can be alternatively spliced to generate a short splice variant, Stk11S, which is
expressed abundantly in Th17 cells.
As we sought to further define the regulatory mechanisms responsible for the
alternative splicing we observed, we identified through RBPmap that the RBP,
hnRNPLL, has strong binding potential on the Stk11 transcript. We found that the level
of expression of hnRNPLL in Th17 cells is much higher than in iTregs. Further leading
us to consider that hnRNPLL mediates Stk11 splicing in Th17 cells. We used RNA
immunoprecipitation to confirm that hnRNPLL, could bind to Stk11S. We confirmed that
functional hnRNPLL is necessary for robust Stk11S processing in Th17 cells by
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demonstrating a significant decrease in Stk11S when we inhibit hnRNPLL using a cellpenetrating antibody. We also demonstrated that Stk11 splicing is a marked feature of a
Th17 phenotype. When Stk11 splicing was inhibited in Th17 cells, through perturbation
of hnRNPLL function, there was a concomitant decrease in Rorc and increase in Foxp3
expression.
The T cell specific kinase, PKC, appears to function at the nexus of Treg-Th17
cell fate choice, preventing induction of iTreg programming while promoting Th17
differentiation. One means by which PKC inhibits Treg function is by mediating TNF
inactivation (Zanin-Zhorov et al., 2010). Conversely, PKC is required for Th17
differentiation in vitro, serving to stabilize RORt (Sen et al., 2018). PKC acts in various
capacities in mature CD4 T cells, from regulating RBPs, such as SC-35, to facilitating
NF-B activation (McCuaig et al. 2015; Shin et al., 2014).
In this study, we demonstrate a relationship between PKC and hnRNPLL
expression. In PKC-/- Th17 cells, Hnrnpll was nearly completely abrogated, further
implicating PKC signaling in regulating alternative splicing machinery. It is unclear how
PKC affects hnRNPLL expression. Our data are consistent with a model whereby
hnRNPLL expression requires intact PKC signaling and is reduced in cells that lack
PKC Figure 2.9. Interestingly, hnRNPLL expression and function is increased with
CD28 co-stimulation (Butte et al., 2012), which has been shown to induce PKC
phosphorylation and recruitment to the immunological synapse (Zanin-Zhorov et al.,
2010). However, is the relationship between hnRNPLL expression and PKC a
byproduct of CD28 signaling? To test this, CD28 engagement would have to be
abrogated. However, this would be a difficult experiment to perform, as T cells
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stimulated in the absence of CD28 undergo anergy (Berg-Brown et al., 2004). This will
need to be investigated by identifying possible PKC functions on hnRNPLL. One
intriguing possibility is that PKC can directly affect the transcription of Hnrnpll. PKC
has been shown to interact with 14-3-3 and NF-B to form a transcriptional complex at
the promoter of various genes to drive cytokine production, including IFN and IL-17
(Sutcliffe et al., 2012). This could be tested using a chromatin immunoprecipitation
assay by immunoprecipitating PKC and using qRT-PCR for Hnrnpll. HnRNPLL
regulates the splicing of numerous transcripts important in T cells (Butte et al., 2012).
As such, further elucidation of the relationship between PKC and hnRNPLL will be
beneficial in determining the regulation of these transcripts and how this affects T cell
function.
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Figure 2.1 In vitro polarization of iTreg and Th17 cells
(A) NP and Th17 cells were analyzed for RORt expression and (B) NP
and iTregs were analyzed for Foxp3 expression through flow cytometry.
To ensure that the iTregs had an iTreg phenotype, we examined CD25 (C)
and nuclear Foxp3 (D) expression using AMNIS imaging flow cytometry.
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Figure 2.2 LKB1 expression in Th17 and iTreg cells
Naïve CD4 T cells were activated and polarized toward a Th17 or iTreg
phenotype. The percent of cells expressing LKB1 (A) and the relative protein
expression (B) were measured by flow cytometry. The number of cells
expressing nuclear LKB1 (C) and the similarity score (D) was analyzed by
AMNIS Imaging flow cytometry. (E) Representative images of nuclear LKB1: the
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Figure 2.3 Gene structure of LKB1
(A) Stk11S is formed by the inclusion of exon9a instead of 9b. Exon 9a is a
cryptic exon found in intron 8 (B) Schematic of the LKB1 primers used in
this study.
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The splice variants of Stk11 were quantified by qRT-PCR. The (A) short and (B) long splice variants, and the
(C) relative short:long transcript ratio are shown. Relative gene expression was determined using the ΔΔCT
method. The results are presented as the fold expression of the gene of interest normalized to the
housekeeping gene β-actin (ACTB) for cells and relative to the NP sample. (D) The short isoform of LKB1
short was visualized by immunoblot, with vinculin as a loading control (left panel). Quantified protein
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expression is shown in the right panel. Data are the mean ± S.E.M of three independent
experiments. Unpaired, two-tailed Student’s t-test was used for analyses; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.5 HnRNPLL binds Stk11S in Th17 cells
(A) HnRNPLL was visualized by immunoblot with vinculin as a loading control with (B) quantified
protein expression. We used RNA-immunoprecipitation to quantify (C) Stk11S bound to hnRNPLL in
Th17 and iTreg cells. Data was analyzed using the ΔΔCt method and values were normalized to
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t-test was used for analyses; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.6 HnRNPLL regulates Stk11S splicing in Th17 cells
We delivered anti-hnRNPLL to Th17 cells and (A) verified its neutralizing effects by assessing CD45
splice variants in Th17 cells differentiated with or without anti-hnRNPLL. Following differentiation, we
quantified (B) Stk11S , (C) Stk11S (D) Stk11S:Stk11L, and (E), Rorc:Foxp3 for Th17 cells left untreated
or treated with anti-hnRNPLL. Stk11S and Stk11L levels were normalized to β-actin and are shown
relative to the Stk11 common primer to account for differences in transcription efficiency between
treated and untreated cells. Relative gene expression was determined using the ΔΔCt method. Data
are the mean ± S.E.M of three independent experiments.
Unpaired, two-tailed Student’s t-test was
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used for analyses; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.7 PKC regulates Stk11S expression
Prkcq expression was determined for (A) Th17 and iTreg cells. To assess the necessity of PKCθ in
LKB1 splicing, WT and PKCθ-/- CD4 T cells were differentiated into NP or Th17 cells. qRT-PCR
was used to quantify the expression of (B) Il17f , (C) Hnrnpll, and (D) Stk11S. Relative gene
expression was determined using the ΔΔCt method. The results are presented as the fold
expression of the gene of interest normalized to the housekeeping gene -actin (ACTB) for cells
and relative to the wild type NP sample. Data are the mean ± S.E.M of three independent
experiments. Unpaired, two-tailed Student’s t-test was used for analyses; NS p>0.05 *p < 0.05; **p
< 0.01; ***p < 0.001; ****p<0.0001.
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Figure 2.8 PKC regulates hnRNPLL and LKB1 expression in iTregs
WT and PKCθ-/- CD4 T cells were differentiated into NP or iTreg cells. The expression of (a)
hnRNPLL and (B) LKB1 was measured by immunoblot with vinculin as a loading control. Data are
the mean ± S.E.M of three independent experiments. Unpaired, two-tailed Student’s t-test was
used for analyses; NS p>0.05
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Figure 2.9 Model of PKC and hnRNPLL regulation of Stk11 splicing
Th17 cells express more Stk11S than iTregs. In Th17 cells, hnRNPLL regulates the
splicing of Stk11S .Inhibition of Stk11 reduces the amount of Rorc:Foxp3. In the
absence of PKC, hnRNPLL and Stk11S expression is diminished.
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CHAPTER 3
IL-6 SIGNALING REGULATES TH17-iTREG PLASTICITY AND METABOLISM
THROUGH ITS REGULATION OF LKB1S AND PKC EXPRESSION

3.1 Introduction
The most striking difference between iTreg and Th17 cells lies in their distinct
metabolic phenotypes. Th17 cells exhibit the most glycolytic phenotype of all the T
helper subsets, while iTreg cells rely on energy processes that are vastly different from
the metabolic phenotypes of all other T helper cells. Th17 cells utilize glycolysis, the
pentose phosphate pathway, OXPHOS, the hexosamine pathway, and FAS, whereas
iTreg cells engage catabolic processes, mainly FAO, to provide energy (Galgani et al.,
2015). It is intriguing to think that T cells can go through such dramatic changes in
metabolism following activation and yet retain the ability to alternate between anabolism
and catabolism. Identifying regulators of metabolic status may lay the foundation for
developing therapeutics to modulate the immune response.
We previously demonstrated that using rotenone to inhibit Complex I of the
electron transport chain (ETC) and subsequent OXPHOS, we attenuated Th17
differentiation but not that of iTregs. Following rotenone treatment, Th17 cells
upregulated Foxp3 expression and exhibited reduced levels of Rorc, suggesting that
these Th17 cells skew toward an iTreg phenotype when OXPHOS is perturbed (Ozay et
al., 2018). It may seem counterintuitive for Th17 cells to lose “Th17-ness” by reducing
Rorc and upregulating Foxp3 expression, in the absence of OXPHOS. However,
although Th17 cells are highly glycolytic cells, they still need OXPHOS for proper T cell
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activation and proliferation consistent with the diminished Rorc in these cells. However,
increased Foxp3 upon Complex I inhibition is surprising as Complex I inactivity is
correlated with Treg suppressive capacity (Angelin et al., 2016). Additionally, Foxp3
expression is important for driving OXPHOS through enhanced expression of OXPHOS
enzymes important in this metabolic pathway (Howie et al., 2017).
A critical branchpoint between Treg and Th17 metabolic phenotypes rests at the
induction of pyruvate oxidation. Glycolysis will induce the conversion of glucose to
pyruvate. The pyruvate can be converted either into lactate and excreted from the cell
or converted to acetyl-coA to feed the TCA cycle, through a process of pyruvate
oxidation mediated by pyruvate dehydrogenase (PDH-e1). Th17 cells resist pyruvate
oxidation through the actions of pyruvate dehydrogenase kinase 1 (PDHK1), which will
phosphorylate and inhibit PDH-e1. PDHK1 activity is important for Th17 effector
function because when it is inhibited in Th17 cells, these cells display a reduced effector
phenotype, characterized by decreased IL-17a expression (Gerriets et al., 2015).
We further explored whether the diminished Th17 phenotype that we observed
following rotenone treatment was due to reduced PDHK1 activity. Using imaging flow
cytometry, we demonstrated that rotenone abrogates the mitochondrial localization of
PDHK1 and PDH-e1. We noted a similar effect when we treated cells with
dichloroacetate (DCA), which also inhibits PDHK1 (Ozay et al., 2018).
Metabolism and plasticity are closely linked and several groups have
demonstrated that perturbing metabolic pathways through pharmacological manipulation
can affect T cell phenotype (Gualdoni et al., 2016; Ozay et al., 2018; Wang et al., 2016).
This effect has been extensively studied in Th17-iTreg plasticity. It has been shown, in
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vitro and in vivo, that Th17 cells can be reprogrammed into FOXP3+ T cells, and
increased percentages of these cells correlated with increased disease survival in the
presence of metabolic inhibitors such as metformin and (aminooxy)acetic acid. As such,
understanding the mechanisms that mediate this plasticity will aid in developing
therapeutics to modulate the immune responses by modulating metabolism. Specifically,
in the case of autoimmunity, iTregs are severely compromised either in number or in
function, or both. Identifying mediators of iTreg stability that preserve suppressive
capacity could help treat autoimmune disorders (Ren and Li, 2017; Sun et al., 2017; Zhou
et al., 2009). It is very peculiar that iTreg and Th17 cells can exhibit plasticity in vitro and
in vivo especially considering the very different functions of these two cell types. Even
more striking is that these two cell types differ dramatically in their metabolic phenotypes.
We noted distinct differences in the expression of the metabolic regulator LKB1 in
Th17 and iTreg cells; therefore, we sought to determine whether isoform expression
correlates with plasticity.
3.2 Results
3.2.1 LKB1 splicing machinery functions downstream of IL-6 signaling
The levels of Stk11S differ between Th17 and iTreg cells and, as such we
postulated that this difference may correlate with the intrinsic plasticity observed
between these two subsets. IL-6 signaling is key to Th17 cell differentiation and IL-6
deficient mice are unable to generate Th17 cells (Nish et al., 2014). Interestingly, IL-6 is
strongly inhibitory towards iTreg differentiation, acting to block Foxp3 expression
(Samanta et al., 2008). Additionally, Th17 cells can transdifferentiate into RORtloFoxp3+-IL-10 expressing cells in vivo (Galgani et al., 2015). We hypothesized that
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LKB1S is a signature feature of Th17 cell identity and not of iTregs. When we
differentiated Th17 cells with anti-hnRNPLL treatment, we saw a reduced ratio of
Rorc:Foxp3 transcript, compared to Th17 cells differentiated with no treatment, Figure
2.6. These results suggested that hnRNPLL may function in modulating Th17-iTreg
plasticity.
The pro-inflammatory cytokine, IL-6, promotes Th17 cell differentiation, in vitro
and in vivo, and IL-6 receptor deficient mice are unable to generate Th17 cells
(Morishima et al., 2009; Nish et al., 2014). IL-6 signals through Janus Kinase (JAK) and
signal transducers and activators of transcription (STAT)3. As such, IL-6 acts to
regulate transcription of Rorc, which encodes the Th17 master transcriptional regulator,
RORt, to drive Th17 differentiation (Zhou et al., 2009). In some in vivo models of colitis,
which are accompanied by high levels of IL-6 expression, Foxp3+ Tregs upregulated
Rorc, suggesting that IL-6 is a key regulator of plasticity between these subsets (Ren
and Li, 2017). Collectively, these observations led us to hypothesize that IL-6 and PKC
may synergize to regulate LKB1 splicing through hnRNPLL. We added IL-6 to iTregs on
day 5 of differentiation, at the same concentration used for Th17 cell polarization. After
24 hours of culture with IL-6, iTregs upregulated hnRNPLL expression, Figure 3.1,
leading to the intriguing possibility that there might also be changes in Stk11 splicing.
Indeed, in differentiating iTregs cultured with IL-6, we observed increased Stk11S,
Figure 3.1. We also detected elevated levels of Rorc transcript, Figure 3.1, indicating
acquisition of a Th17-like phenotype.
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3.2.2 PKC expression is regulated by IL-6 signaling
Our data indicated that PKC regulated the expression of hnRNPLL in Th17
cells, (Figure 2.7), and that IL-6 signaling upregulated hnRNPLL in iTregs, (Figure 3.1).
Furthermore, it has been shown that IL-6 and PKC activity can both destabilize the
Treg phenotype. Since we observed IL-6 and PKC regulated hnRNPLL expression
and, consequently, Stk11 splicing, we hypothesized that IL-6 signaling might also
induce PKC expression. As we predicted, when iTregs were treated with IL-6, Prkcq,
the gene encoding PKC, was strongly upregulated, Figure 3.2. This indicates that T
cells respond to the presence of IL-6 by upregulating Prkcq. Collectively, these data
support an outside-in signaling pathway whereby iTregs respond to the presence of IL-6
by upregulating Prkcq, re-expressing hnRNPLL, and generating higher levels of Stk11S
to facilitate iTreg to Th17 plasticity.
We were intrigued by this finding because the only previously reported
connection between IL-6 and PKC was through PKC-mediated STAT3 upregulation in
Th17 cells. We hypothesized that this mechanism may proceed, in part, through the
upregulation of hnRNPLL, downstream of IL-6 signaling. Using the RBPmap algorithm,
we examined the Prkcq sequence for hnRNPLL binding sites. We were surprised to find
numerous potential hnRNPLL binding sites in the sequence. We performed RNAimmunoprecipitation, as previously described, immunoprecipitating transcripts bound to
hnRNPLL. Using qRT-PCR, we established that hnRNPLL binds to Prkcq in Th17 cells
but not in iTreg cells, Figure 3.2. These data suggest, in fully differentiated iTregs, that
IL-6 signaling upregulates hnRNPLL and, subsequently, induces the expression of
PKC These novel observations provide some insight as to how IL-6 negatively
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regulates Treg programming through its effects on hnRNPLL and PKC culminating in
alterations of Stk11S expression levels.
3.2.3 Pharmacological perturbation of lactate production reduces Stk11S
The LKB1-AMPK pathway is best known for functioning as a metabolic sensor, shifting
cells towards energy preservation pathways to effectively block anabolic pathways such as
glycolysis, and promoting catabolic pathways such as fatty acid oxidation (Lochner et al., 2015).
Th17 cells are highly glycolytic; therefore, we found it surprising that these cells expressed such
high levels of LKB1. Further, perturbating metabolism has been shown to modulate T cell
phenotypes (Ren and Li, 2017). As such, we hypothesized that hnRNPLL promotes Stk11
alternative splicing in Th17 cells, to prevent changes in metabolism, and the effects of Stk11
splicing following anti-hnRNPLL delivery supports this notion, Figure 3.1. When T cells are
activated, they utilize glycolysis to convert glucose to pyruvate which will then be converted to
lactate and excreted from the cell. This mode of energetics is also used by effector T cells after
activation. Treg cells do not use glycolysis as a primary means of deriving energy. Instead of
breaking-down glucose via glycolysis, Treg cells preferentially break down fatty acids and
proteins to fuel the TCA cycle (Galgani et al., 2015).
On the infrequent occasion that glycolysis occurs in Tregs, the pyruvate generated will
be converted to acetyl-coA to feed into the TCA cycle. Pyruvate is processed into acetyl-coA
through the actions of PDH. PDH activity is regulated by PDHK1 which will phosphorylate and
inactivate PDH, allowing pyruvate to be converted into lactate and excreted from the cell. Th17
cells express higher levels of PDHK1 than do Tregs or even Th1 cells. Altogether this supports
a model whereby Th17 cells are highly reliant on glycolysis, and concomitant lactate production.
As such, inhibition of acetyl-coA production is a fundamental feature of Th17 biology (Gerriets et
al, 2015).
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We hypothesized that LKB1S may be generated as a mechanism to maintain glycolysis.
To test this, we differentiated Th17 cells and treated them during the last 48 hours of
differentiation with dichloroacetate (DCA) which inhibits glycolysis by inhibiting pyruvate
dehydrogenase kinase (PDHK), a kinase that blocks pyruvate oxidation (Gerriets et al., 2015).
We validated that DCA treatment inhibited glycolysis by assessing transcript levels of
hexokinase 2 (HK2), an enzyme required for glycolysis, Figure 3.3. Following DCA treatment,
Stk11S transcript was abrogated while Stk11L remained relatively constant, Figure 3.3.
Additionally, Th17 cells treated with DCA showed a markedly decreased ratio of Stk11S:Stk11L,
Figure 3.3, consistent with the results we observed when we delivered anti-hnRNPLL, Figure
2.6. These experiments demonstrate for the first time that LKB1 isoform expression is
associated with, and changes with, the metabolic profile of the Th17 cells.
When Stk11S alternative splicing was attenuated, the ratio of Rorc:Foxp3 was lowered
concomitantly, Figure 2.6, suggesting these cells were adopting an iTreg-like phenotype. Given
its effects on Stk11 splicing, we asked whether DCA treatment would also destabilize the Th17
phenotype. We noted diminished expression levels of Rorc in DCA-treated Th17 cells, Figure
3.4, thus linking Stk11 splicing and plasticity to metabolic status.
Futhermore, we observed that Prkcq was induced by upstream IL-6 signaling and that
this correlated with hnRNPLL expression, Figure 3.1. Additionally, we demonstrated that both
Stk11S and Prkcq transcripts were enriched in hnRNPLL-immunoprecipitated Th17 lysates
(Figure 2.5 and 3.2). Therefore, we asked whether Prkcq expression would be impacted
similarly to that of Stk11S when glycolysis is perturbed. We noted a significant reduction in Prkcq
expression in Th17 cells, treated with DCA, Figure 3.4. Collectively, these data provide
evidence of a highly integrated network that links metabolic state with Rorc and Prkcq
expression, as well as with Stk11 alternative splicing.
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3.3 Discussion

In this study, we asked whether there was a relationship between Stk11 splicing,
plasticity and metabolism. We showed that IL-6 signaling upregulated hnRNPLL
expression and subsequently increase Stk11S expression. We also demonstrated for the
first time that IL-6 signaling acts upstream of and positively regulates PKC by increasing
Prkcq transcription. To further tease out the mechanism of Prkcq upregulation, we asked
if hnRNPLL, which is also induced by IL-6, modulated Prkcq transcription. We found by
RNA-immunoprecipitation, that hnRNPLL binds to Prkcq transcript in Th17 cells but not
in iTregs. Previous studies demonstrated IL-6 acts to inhibit Treg differentiation and
function (Brezar et al., 2015; Zanin-Zhorov et al., 2010) and the data we provide linking
IL-6 to Prkcq regulation fills a critical gap in our understanding of how IL-6 signaling acts
to destabilize the Treg phenotype.
LKB1 functions in effector T cells have not been fully elucidated. In peripheral T
cells, LKB1 depletion increased glycolysis, cell death, and cytokine production by Th1
and Th17 cells (MacIver et al., 2011). LKB1 has been shown to mediate fatty acid
metabolism and this feature is critical for Treg function (Timilshina et al., 2019) and
contrastingly act in pathways to inhibit glycolysis (Ma et al., 2017). As Th17 cells are
highly glycolytic, our results beg the question whether the splicing of Stk11 in Th17 cells
is necessary to maintain glycolysis. This is based on our observation that when we used
DCA to inhibit glycolysis in Th17 cells, we also attenuated Stk11S expression, highlighting
a reciprocal relationship between Stk11S expression and maintaining glycolysis. Whether
or not Stk11 splicing defines the metabolic state of Th17 cells, remains to be elucidated.
What we can conclude, however, is that IL-6 signaling promotes Stk11S transcription, and
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this proceeds via PKC and hnRNPLL, Figure 3.5. Altogether, our data suggest that LKB1
splicing may be central to mediating iTreg-Th17 plasticity.
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Figure 3.1 IL-6 signaling induces hnRNPLL and Stk11S expression in iTregs
iTregs were dosed with 20ng/mL of IL-6 of day 5 of the differentiation culture. Cells
were harvested 24 hours later. We used immunoblotting to determine (A)
hnRNPLL expression and used qRT-PCR to quantify (B) Stk11s, (C) Rorc. Relative
gene expression was determined using the ΔΔCt method. The results are
presented as the fold expression of the gene of interest and normalized to β-actin
(ACTB) and relative to the untreated iTreg sample. Data are the mean ± S.E.M of
three independent experiments. Unpaired, two-tailed Student’s t-test was used for
analyses; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.2 IL-6 and hnRNPLL regulate PKC expression
iTregs were dosed with 20ng/mL of IL-6 of day 5 of the differentiation culture.
Cells were harvested 24 hours later. We used qRT-PCR to quantify Prkcq
expression (A) and from transcripts immunoprecipitated to hnRNPLL (B). Relative
gene expression was determined using the ΔΔCt method. The results are
presented as the fold expression of the gene of interest and normalized to β-actin
(ACTB) and relative to the untreated iTreg sample (A) or NP (B). Data are the
mean ± S.E.M of three independent experiments. Unpaired, two-tailed Student’s
t-test was used for analyses; *p < 0.05; ***p < 0.001.
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CD4 T cells were differentiated under Th17 polarizing conditions. During the last
48 hours of differentiation, Th17 cells were dosed with 10mM of dichloroacetate
(DCA). DCA effects on glycolysis were confirmed by quantifying transcript of (A)
Hexokinase2. We used qRT-PCR to assess the effects on DCA treatment on (B)
Stk11S, (C) Stk11L, (D) Stk11S:Stk11L. Relative gene expression was determined
using the ΔΔCt method. The results are presented as the fold expression of the
gene of interest normalized to the housekeeping gene β-actin (ACTB) for cells and
for (A) relative to the untreated Th17 sample and for (B-D) and relative to the
common primer to account for differences in overall Stk11 transcription levels.
Data are the mean ± S.E.M of three replicates and are representative of three
independent experiments, each of which showed similar results. Unpaired, twotailed Student’s t-test was used for analyses; *p < 0.05; ***p < 0.001; ****p<0.0001.
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Figure 3.4 Modulating Th17 cell metabolism diminishes Th17 phenotype
CD4 T cells were differentiated under Th17 polarizing conditions. During the last 48
hours of differentiation, Th17 cells were dosed with 10mM of Dichloroacetate (DCA).
We used qRT-PCR to assess the effects on DCA treatment on (A) Rorc, and (B) Prkcq.
Relative gene expression was determined using the ΔΔCt method. The results are
presented as the fold expression of the gene of interest normalized to the
housekeeping gene β-actin (ACTB) for cells and for relative to the untreated Th17
sample. Data are the mean ± S.E.M of three replicates and are representative of three
independent experiments, each of which showed similar results. Unpaired, two-tailed
Student’s t-test was used for analyses; **p < 0.01; ***p < 0.001.

79

Figure 3.5 IL-6 signaling induces Stk11S and PKC expression
IL-6 signaling in combination with CD28 engagement induce the expression of Prkcq
and hnRNPLL. hnRNPLL modulates the splicing of Stk11S and regulates Prkcq
transcript. When hnRNPLL function is intact, there is more Rorc than Foxp3 transcript
in the cell, suggesting a Th17 phenotype. When glycolysis is inhibited Stk11S, Rorc,
and Prkcq expression is also inhibited. iTregs will yield a similar phenotype upon IL-6
stimulation to facilitate iTreg to Th17 plasticity.

80

CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Conclusions
In this study, we describe for the first time a connection between LKB1 isoform
expression, metabolism, and plasticity between Th17 cells and iTregs. LKB1 has been
identified as a mediator of Treg induction and function through its effects on TSDR
methylation and on cell metabolism. We demonstrate that LKB1 is expressed in both
Th17 and iTreg cells, and to a much higher extent in Th17 cells. LKB1 can be
expressed as one of two isoforms: short and long, which differ in their expression of
exon 9. We have determined that LKB1s is predominately expressed in Th17 cells and
LKB1L is expressed more abundantly in iTreg cells. We provide evidence that the
isoform expression correlates with the phenotypic stability observed between Th17 cells
and iTregs. As such, when IL-6, which is inhibits the Treg differentiation programming,
is administered to iTregs, we observe increased levels of Stk11S. Moreover, we
demonstrate that IL-6 also upregulates PKC in iTregs and expression of PKC
correlates with LKB1s expression. Finally, we provide evidence that LKB1 isoforms also
correlate with the metabolic state of Th cells, because when we inhibit glycolysis, we
see concomitant decrease in LKB1s levels in Th17 cells. This work reports, for the first
time, data linking IL-6, PKC, and metabolic changes to differences in LKB1 isoform
expression as being functionally relevant contributors to the plasticity of Th17 cells and
iTregs.
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4.2 Future Directions
4.2.1 HnRNPL and Stk11 regulation
Heterogenous nuclear ribonuclear protein L (hnRNPL) shares sequence similarity to
hnRNPLL and both proteins preferentially bind to dinucleotide CA repeats. According to
the RBPmap algorithm, hnRNPL also demonstrates strong binding potential to Stk11
transcript. Additionally, hnRNPL has been shown to inhibit cryptic exon inclusion. As
such, we hypothesized that hnRNPL may block the splicing of Stk11 short by blocking
exon9a which is a cryptic exon, Figure 2.3, and this could account for the differences in
Stk11 isoforms seen between Th17 and iTreg cells. We hypothesized that perhaps
there may be differences in hnRNPL binding to Stk11 transcript in Th17 versus iTreg
cells. Specifically, we expected to see more binding of hnRNPL to Stk11L, as this
interaction would be increased. We performed RNA-immunoprecipitation using antihnRNPL to immunoprecipitate target transcripts. Using qRT-PCR as an output, we
observed that hnRNPL did bind to Stk11S and this was more prevalent in Th17 cells
than in iTregs. Furthermore, hnRNPL binding to Stk11L was detectable both in Th17
and iTreg cells, Figure 4.1. However, it remains unclear whether hnRNPL binding
blocks or drives the splicing of Stk11. To ask this question, we will need to conduct an
antibody delivery experiment to hnRNPL, as done in Figure 2.6 and assess what
happens to Stk11 transcript when hnRNPL is functionally inhibited. If there are higher
levels of Stk11S, we can postulate that hnRNPL inhibits Stk11 splicing.
Since we demonstrated more RNA binding, as well as increased Prkcq transcript,
in Th17 cells we hypothesized that PKC may regulate the expression of hnrnpl.
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However, we did not find a significant different in hnrnpl transcript expression WT and
PKC-/- Th17 cells.
We next asked if, hnRNPL bind to PKC and, thus, might hnRNPL regulation
proceed through its physical interaction? When we immunoprecipitated hnRNPL, we
noted that it associated with PKC both in Th17 and iTreg cells, Figure 4.1, suggesting
preferential binding may not regulate hnRNPL expression.
In Ozay et al. (2020) our group determined that nuclear hnRNPL is diminished in
human iTreg cells treated with anti-phospho-PKC(T538), delivered intracellularly, while
the cytosolic localization of hnRNPL is increased. This suggests that PKC may function
in hnRNPL cytoplasmic-nuclear shuttling. HnRNPL is one of the hnRNP proteins that
can shuttle and aids in cytoplasmic transcript accumulation (Kim et al., 2000). As PKC
seems to be a regulator to Th17-iTreg plasticity, we hypothesized that hnRNPL
localization would be primarily cytosolic in the absence of PKC in Th17 cells. We
examined cytoplasmic and nuclear extracts from WT and PKC-/- Th17 cells and
observed that nuclear hnRNPL was higher in PKC-/- Th17 cells as compared to WT
Th17 cells, suggesting that PKC may act to regulate hnRNPL transport out of the
nucleus, Figure 4.1. If hnRNPL is indeed inhibitory to Stk11S expression, this finding
could further explain why there is less Stk11S expression in the absence of PKC.
However, this data is preliminary and needs to be further validated.
Additional studies are needed to further tease out how exactly PKC regulates
hnRNPL cellular localization. Since we observe a similar phenotype in iTreg cells and
PKC-/- Th17 cells in regards to Stk11 expression, we can postulate that what we see in
the PKC-/- Th17 would be similar to WT iTregs. However, since we noted that hnRNPL
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can bind Stk11S, the isoform which is more highly expressed in Th17 cells than in iTregs
or in PKC-/- Th17 cells, there is much we have yet to learn about how hnRNPL
functions in Stk11 splicing.
If hnRNPL does have a role in regulating Stk11, it will be useful to determine if
hnRNPL acts in the cytoplasm or in the nucleus. This can be answered, in part, by the
antibody delivery experiment already mention and RNA-immunoprecipitation to further
validate the binding of hnRNPL to transcript. We can then determine where this
interaction occurs by separating cytoplasmic and nuclear RNA. Amplifying each cellular
RNA fraction using qRT-PCR, we can determine whether this interaction is primarily
cytosolic or nuclear. We can also perform this experiment using PKC-/- Th17 cells, to
determine whether this is a PKC-mediated phenomenon.
4.2.2 LKB1-Notch1 interactions in Th17 plasticity
In cardiomyocytes, LKB1 can interact with Notch1 which enables LKB1 to
activate AMPK (Yang et al., 2016). Notch1 is a transmembrane protein that is activated
by one of several ligands and then is sequentially cleaved by ADAM proteases and
gamma-secretase. Notch1 has many different roles in T cell activation and
differentiation (Osborne and Minter, 2007). Our group has shown that Notch1 interacts
with PKC in the lipid rafts and this interaction functions to drive the activation of the
CARMA1-BCL10-MALT1 complex and resultant NF-B activation (Shin et al., 2014).
However, in ex vivo-expanded cord blood Treg cells, PKC was found to be
sequestered away from the immunological synapse upon T cell activation. Additionally,
inhibition of PKC led to the increased suppressive activity of these Treg cells (ZaninZhorov et al., 2010).
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LKB1 has been shown by numerous studies to be imperative to Treg survival and
suppression (He et al., 2017; Timilshina et al., 2019; Wu et al., 2017; Yang et al., 2017).
As such, we hypothesized that with the absence of PKC in the lipid rafts, Notch1 would
preferentially bind to LKB1 in iTreg cells, whereas in effector cells, such as Th17 cells,
Notch1 would preferentially bind to PKC. In order to investigate this hypothesis, we
stained iTreg and Th17 cells with antibodies specific for Notch1 and LKB1, then utilized
stochastic optical reconstruction microscopy (STORM) to visualize differences in protein
localization between the two cell types. Surprisingly, we saw that there were more
overlapping regions in the Th17 cells as compared to the iTregs. Using a colocalization
algorithm, we determined that Th17 cells have a higher degree of colocalization as
compared to the Treg cells, Figure 4.2. We will follow up this preliminary experiment
using an immunoprecipitation assay to confirm the microscopy data. If we can confirm
the microscopy data, the following work should provide a means of assessing the
functional output of this interaction.
Our hypothesis is that the interaction between Notch1 and LKB1 may be tissuecontext specific and thus in the Th17 cells, we predict Notch1-LKB1 interaction may
modulate AMPK activity in a cell-type-specific manner. Previously, we established that
Notch1 is associated with mitochondria more in iTregs than Th17 cells (Ozay et al.,
2018). LKB1 has been reported to only reside in the nucleus or the cytoplasm (Zhu et
al., 2009). As such, we can hypothesize that the differences in binding are due to
protein accessibility of Notch1. We saw that the levels of nuclear LKB1 were relatively
consistent both in Th17 cells and in iTregs, so we would predict that differences in
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LKB1-Notch1 interaction may be because Notch1 accessibility is rate-limiting, Figure
2.2.
Interestingly, despite the inhibitory effect of AMPK on mTORC1, AMPK is
essential, in vivo, for Th17 function (Blagih et al., 2015). However, one of the functions
of AMPK is to inhibit the FAS enzyme, acetyl-CoA carboxylase 1, ACC1, which is
imperative to Th17 development and acts to inhibit Treg development (Berod et al.,
2014). Moreover, inhibition of AMPK or FAS can induce interferon  (IFN) expression
(Blagih et al., 2015; Young et al., 2017). This suggests that inhibiting fatty acid synthesis
may regulate the transition of a Th17 cell into a pathogenic Th1-like phenotype, which
are known to contribute to autoimmune diseases, such as multiple sclerosis (Young et
al., 2017). Although it is unknown if Notch1 or LKB1 regulates the transition of a Th17
cell into a pathogenic Th-like cell. We hypothesize that a basal level of Notch1-LKB1
colocalization in the Th17 cells, as compared to iTregs, would position Th17 cells to
readily adopt this more pathogenic phenotype.
To test these hypotheses after the initial confirmation by immunoprecipitation of
interaction differences between the two cell types, we would want to explore the
functional characteristics of this interaction. First, we can validate a tool to disrupt the
interaction between Notch1 and LKB1 in Th17 cells. If this interaction relies on activated
Notch1, we can use a gamma secretase inhibitor (GSI), to block Notch1 activation and
use this as a tool to block the interaction. First, we will examine the activation of AMPK
resultant activation of p-ACC1 by immunoblot in the presence or absence of GSI. If we
observe changes in AMPK and p-ACC1 levels when Notch1 is inhibited, we can
conclude that Notch1 activation is necessary for downstream of AMPK and p-ACC1

86

activity. Next, we can ask whether Th17 cells, treated with IL-23 and/or IL-1 to induce
a pathogenic phenotype, have increased p-ACC1 and p-AMPK, as assessed by
western blot? Further, if the Notch1-LKB1 interaction is important in FAS and resultant
pathogenicity of Th17 cells, we would expect that upon GSI treatment of the pathogenic
Th-like cells, there would be a diminution in the expression levels of p-ACC1 and pAMPK? Elucidation of the function of Notch1-LKB1 interactions in Th17 cells may
provide interesting insights into Th17 plasticity and uncover targets for therapeutic
manipulation.
4.2.3 Regulation of PKC expression downstream of IL-6 signaling and hnRNPLL
In Figure 3.2, we show that the expression of Prkcq can be induced through IL-6
signaling. Since IL-6 signaling also induced hnRNPLL, we asked if hnRNPLL can
regulate Prkcq transcript. We saw that hnRNPLL binds to Prkcq to a greater degree in
Th17 than in iTreg cells, and this was not due to the lower levels of Prkcq transcript
found in iTreg cells (Figure 2.6). We are confident of this because during our analyses,
the RNA immunoprecipitation data were normalized to Prkcq expressed in iTregs or in
Th17 cells, thereby taking into account any differences in transcript levels between cell
types.
These data lead us to further question whether the IL-6-mediated effect on Prkcq
transcript is solely through its effects on hnRNPLL or is a broader feature of IL-6
signaling, itself. IL-6 signals through JAK kinases to activate STAT3 to modulate gene
expression (Schaper and Rose-John, 2015). One means of investigating the hypothesis
that IL-6 signaling induces Prkcq expression through STAT3 is to perform a chromatin
immunoprecipitation (ChIP) assay on the promoter region of Prkcq to determine if
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STAT3 binding occurs, or is enhanced, following IL-6 treatment. If we do not detect
increased STAT3 occupancy on the Prkcq promoter, we will need to assess other, less
direct means by which IL-6 may influence Prkcq expression, such as those exerted by
hnRNPLL.
As shown in Figure 3.2, we observed that hnRNPLL can bind Prkcq transcript.
We can hypothesize that hnRNPLL is necessary for Prkcq transcript regulation, as we
noted the same pattern of high Prkcq expression in Th17 and its low expression in iTreg
cells, as measured both by overall transcript levels, and in the amount of transcript
bound to hnRNPLL, Figure 3.2. To determine the requirement for hnRNPLL in Prkcq
transcription and translation, we can block hnRNPLL activity by delivering antihnRNPLL into Th17 cells, which have ample PKC. If we observe a significant
difference in Prkcq levels following anti-hnRNPLL treatment, compared to controls, we
can conclude that hnRNPLL is necessary for Prkcq transcript processing and/or
stability. These experiments would allow us to uncouple IL-6 signaling from the actions
of hnRNPLL and further determine which signal is more important in Prkcq expression.
From here, we could further investigate whether hnRNPLL is necessary at the level of
Prkcq transcriptional or translational processing.
4.2.4 Does LKB1 confer phenotypic stability in Tregs?
A crucial obstacle in Treg therapy is destabilization of the Treg phenotype after
transplantation. A key feature of Treg phenotypic stability is the methylation of the
TSDR within the Foxp3 gene locus. Several trials have tried to profile the methylation
status of Tregs prior to transplantation to ensure a stable Treg population to the patient.
However, even with this precaution, some reports indicate that the Treg therapy is not
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entirely efficacious and may even exacerbate inflammation. In Dall’Era et al. (2019),
after 12 weeks of Treg therapy, although the percentages of IFN-producing CD4 and
CD8 T cells decreased, there was an increase in IL-17-producing CD4 and CD8 T cells,
compared to baseline. The overall population of Treg cells, characterized as
CD4+CD25+ cells, increased slightly. However, the percentage of CD4+CD25+IL-17+
cells also increased, suggesting that the transplanted Tregs may be subject to
conversion to IL-17 producing cells, in vivo (Dall’Era et al., 2019). These data support a
scenario whereby, despite selecting Tregs with a highly demethylated TSDR, these
“stable” Tregs cells do not necessarily remain phenotypically stable over time, following
transplantation.
LKB1 is a protein of interest regarding Treg stability due to its regulation of fatty
acid metabolism, which is crucial to Treg function. It has been shown that LKB1 blocks
STAT 4-mediated methylation of the TSDR, to promote stable Tregs. Furthermore,
inhibiting LKB1 in the Treg compartment results in systemic autoimmunity, due to a
failure of LKB1-/- Tregs to suppress aberrant immune responses (Wu et al. 2017).
Additionally, Foxp3 expression is contingent on LKB1 expression, as delivering an
shRNA against LKB1 reduced Foxp3 expression, while overexpressing LKB1 increased
Foxp3 expression (Su et al., 2019). On the contrary, when LKB1 is knocked out in T
cells, effector T cells produce higher levels of cytokines. However, it is not entirely clear
whether this phenomenon results from faulty thymocyte development, enhanced
effector T cell function, or diminished Treg suppression (MacIver et al., 2011). An
intrinsic role for LKB1 in effector cells has not been described. However, data in the

89

literature that describes a function for LKB1 in driving catabolic metabolism, suggest
that LKB1 would act to negatively regulate effector T cell function.
In acute Graft-versus-Host Disease, patient Tregs show reduced functionality
and this correlated with low LKB1 expression in the Tregs (Su et al., 2019). In another
study, it was determined that LKB1-/- Tregs can secrete inflammatory cytokines, such as
IL-17, and when introduced into a host can cause a pro-inflammatory response. This
response was related to faulty fatty acid metabolism that occurs in the absence of LKB1
and could be reversed with the addition of fatty acid metabolites (Timilshina et al.,
2019). LKB1 is essential to Foxp3 expression, Treg metabolism, and suppressive
capacity, making it clear that enhancing LKB1 in Tregs may reasonable therapeutic
approach in treating autoimmune disorders.
In this study we provide evidence that implicates LKB1S as a mediator of Th17iTreg plasticity. Due to the high correlation between Foxp3 and LKB1, further work
needs to be done to determine whether ex vivo LKB1 manipulation would produce a
population of highly stable Tregs. We demonstrate that downstream of IL-6, a cytokine
that induces IL-17 secretion and inhibits Foxp3 expression, PKC and hnRNPLL act
either separately or in association, to induce LKB1S expression. Furthermore, we show
that when we perturb anabolic metabolism in Th17 cells, we also attenuate LKB1
splicing. This leads to the question of whether blocking LKB1 splicing into its short
isoform, either partially or completely, results in more stable Tregs.
To test the effect LKB1S has on Treg stability we can perform several
experiments. First, we can overexpress LKB1S in Tregs and assess cytokine
production. Specifically, is there a correlation between LKB1S expression and the
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production of proinflammatory cytokines? Furthermore, how does LKB1 S overexpression
affect TSDR methylation? This can be evaluated using bisulfite sequencing.
If we correlate LKB1S isoform expression with Treg instability, can we target this
pathway to stabilize the Treg phenotype? Our group has previously shown that
delivering anti-pPKC into CD4 T cells prior to differentiating them into iTregs makes
them more potent suppressors, both in vitro and in vivo. Since we have demonstrated
that PKC is induced by the proinflammatory cytokine, IL-6, and is involved in the
regulating LKB1 splicing, we can hypothesize that inhibiting PKC using an antibody
delivery strategy may make iTreg cells more resistant to destabilization when
challenged with IL-6. To explore this hypothesis, we can repeat the experiment outlined
in Figure 3.1, using iTregs that received anti-pPKC prior to stimulation. Our readouts
for assessing iTreg stability in the presence of IL-6 would be to compare the TSDR
demethylation patterns, Stk11 splice variants, and proinflammatory cytokine production
in anti-pPKC-treated and untreated iTregs. If anti-pPKC treatment increased iTreg
stability, we would expect to see protected TSDR demethylation, reduced Stk11S (or
relative increases in Stk11L), and reduced IL-17 secretion.
We would prefer to perform this experiment first with anti-pPKC, as hnRNPL
and hnRNPLL are involved in CD45 splicing (Wu et al., 2008; Rothrock et al., 2005).
Different isoforms of CD45 are expressed on different types of T cells such as naïve
and memory phenotypes providing a means of isolating these cell types in a
heterogenous population (Wu et al., 2008). The function of specific CD45 isoforms in
Treg biology has not been fully elucidated; however, it has been reported that a
population of memory Treg cells that express the CD45RA isoform show a higher
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degree of TSDR demethylation at Foxp3 locus. This population of CD45RA+ Tregs has
been documented in patients who have tolerated kidney transplantation well, lending
the support of clinical data to this hypothesis (Braza et al., 2014). As such, although
anti-hnRNPL or -hnRNPLL may also reduce LKB1 splicing, this inhibition may have offtarget effects on CD45 that could produce confounding results.
4.2.5 LKB1S expression and Th17 function
To our knowledge, our study is the first to identify high expression of LKB1,
specifically of LKB1S, in Th17 cells. We demonstrated that, in iTregs, IL-6 upregulates
hnRNPLL and increases the levels of Stk11S. We would like to further investigate
whether Stk11S is necessary and sufficient to establish the Th17 differentiated
phenotype. TGF- and IL-6 synergize to induce RORt expression of and subsequent
IL-17 production (Xiao et al., 2008). In order to test if LKB1S induction is sufficient to
induce cells to adopt a Th17 identity, we can overexpress LKB1 S in naïve T cells and
stimulate them with Th17 polarization media. After culturing for 5-7 days, we can use
flow cytometry to assay for IL-17 and IL-23 production, as well as for RORt expression.
If there is an increase in cytokine production and/or an increase of RORt expression,
compared to cells not transfected with LKB1S, we can conclude that LKB1S expression
is beneficial to the induction of the Th17 phenotype.
We noted that, when we perturbed glycolysis in Th17 cells, there was a decrease
in LKB1S expression. These Th17 cells still expressed Rorc, but also showed increased
Foxp3. These observations beg the questions: “Is decreased LKB1S expression due to
overall cellular dysfunction?” “Or does inhibiting glycolysis also block Stk11 splicing?”
Another way to ask the latter question is to rephrase it: “Do T cells express LKB1S, as
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opposed to LKB1L, to preserve a glycolytic state?” To answer this question, we can
isolate RNA from Th17 cells in which LKB1s is overexpressed and ask whether the
levels of glycolytic enzymes are enhanced, compared to control cells. Reciprocally,
when LKB1S is introduced into iTreg cells, does this also induce glycolytic enzyme
expression? Data that link LKB1S expression to induction or enhancement of glycolytic
enzymes may serve to close an important gap in our understanding of Th17-iTreg
plasticity, from the standpoint of metabolic differences.
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Figure 4.1 HnRNPL regulation of Stk11 splicing may be regulated by PKC
We used RNA-immunoprecipitation to quantify (A) Stk11S and (B) Stk11L bound to
hnRNPL in Th17 and iTreg cells. WT and PKCθ-/- CD4 T cells were differentiated into
NP or Th17 cells. qRT-PCR was used to quantify the expression of (C) hnrnpl. Data
was analyzed using the ΔΔCt method and values were normalized to input (A-B) and
WT NP (C). (D) HnRNPL was immunoprecipitated and immunoblotted for PKC to
detect binding and with tubulin as a loading control. Data are the mean ± S.E.M of
three independent experiments. Unpaired, two-tailed Student’s t-test was used for
analyses; NP p>0.05; *p < 0.05; **p < 0.01; ***p < 0.001. (E) Cytoplasmic and nuclear
extracts were isolated from WT and PKCθ-/- CD4 T cells were differentiated into NP or
Th17 cells and probed for hnRNPL. Data is normalized to HDAC1 for nuclear protein.
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Figure 4.2 LKB1 and Notch1 colocalize in Th17 cells
We STORM to detect differences in LKB1 and Notch1 colocalization. (A) STORM
images of Th17 cells and iTregs. Notch1 is in red and LKB1 is in green. (B) The
correlation coefficient was determined using a Matlab script from Colorado State
University. Data are the mean ± S.E.M of cell images per cell type. Unpaired, two-tailed
Student’s t-test was used for analyses; **p < 0.01.
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CHAPTER 5
MATERIALS AND METHODS

5.1 Animals
C57BL/6 mice were purchased from The Jackson Laboratory. PKC-/- mice (C57BL/6
background) were bred in house. All animal protocols were approved by the Institutional
Animal Care and Use Committee of the University of Massachusetts, Amherst.
5.2 In vitro T cell polarization
CD4 T cells were isolated from spleens using Mojosort (Biolegend). Cells were
stimulated on plates coated with anti-hamster IgG (Sigma-Aldrich), anti-CD3e (clone
145-2C11; Biolegend) and anti-CD28 (clone 37.51; BD Biosciences). iTreg cultures
were stimulated with these same clones using plate-bound anti-CD3e and soluble antiCD28. Cells were incubated in a 1:1 mixture of RPMI and DMEM, (Hyclone),
supplemented with L-glutamine, sodium pyruvate, pen-strep (GE Life Sciences) and
fetal bovine serum (Peak Serum), and 0.34% -mercaptoethanol. Cells were cultured
for 7 days under the following polarizing conditions: Non-polarized (NP): IL-2 (135U/mL;
Biolegend); Th17: IL-6 (20ng/mL), TGF-β (5ng/mL; both from Biolegend), anti-IFN
(10ug/mL, clone XMG 1.2; BioXcell), anti-IL-4 (10ug/mL, clone 41B11; Biolegend and
BioXcell); iTreg: IL-2 (135U/mL), TGF-β (20ng/mL), Retinoic Acid (2.5nM, SigmaAldrich).
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5.3 Flow cytometry
Cells were processed using a Luminex ImageStreamx mkII imaging flow cytometer.
Cells were fixed and permeabilized with the Foxp3/Transcription Factor Staining Buffer
Set (eBioscience). Antibodies used for staining: CD4 FITC (clone H129.19), CD25 APC
(clone PC96), Foxp3 PE (clone FJK-16s), Foxp3 PE (clone 150D; all from BD
Biosciences), LKB1 (clone D60C5; Cell Signaling Technologies), RORγt PE (clone
AFKJS-9; eBioscience), and F(ab’)2 IgG QDot625 (Life Technologies). Nuclei were
stained using DRAQ5 (ThermoFisher Scientific) Analyses were made using IDEAS,
(Luminex Corporation).
5.4 Quantitative Real Time -PCR
RNA was isolated from cells with the Quick-RNA Mini-Prep kit (Zymo Research). cDNA
was synthesized with Oligo(dt) 12-18 primer (ThermoFisher Scientific), m-MLV reverse
transcriptase and RNasinⓇ plus inhibitor (Promega Corporation), and dNTPs (New
England Biolabs). cDNA was used in qRT-PCR reactions with SYBR Green Master Mix
(Bimake).

Reactions

were

conducted

using

a

Stratagene

Mx3000p

(Agilent

Technologies). Data were analyzed using the Ct method. Primer sequences
(Integrated DNA Technologies) are listed in Table 5.1.
5.5 Immunoblotting
Cells were lysed in RIPA buffer in the presence of phosphatase and protease inhibitors
(Bimake). Protein lysates were resolved on an 8% SDS-PAGE gel and transferred onto
a nitrocellulose membrane and blocked with 5% non-fat milk dissolved in 0.2% Tween20 in PBS. Antibodies used for immunoblotting: hnRNPLL, alpha-tubulin (Cell Signaling
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Technologies),

Vinculin

(ProteinTech),

LKB1

(clone

Ley37/D6;

Santa

Cruz

Biotechnologies), hnRNPL (clone 4D11; Novus Biologicals. Secondary antibodies used:
anti-mouse IgG HRP (GE Amersham) and anti-rabbit IgG (Cell Signaling Technologies
and GE Amersham).
5.6 RNA-Immunoprecipitation
Cells were lysed in IP Buffer (Tris-HCL pH 8.0, 200nM NaCl, 0.1% NP-40) in the presence
of phosphatase and protease inhibitors (Bimake) and RNasin Ⓡ plus inhibitor (Promega).
Dynabeads protein GⓇ (ThermoFisher Scientific) were coated with anti-hnRNPLL (Cell
Signaling Technologies) at room temperature in a solution of 1% BSA (Rocky Mountain
Biologicals) in PBS. Lysates and beads were incubated together for 1 hour at 4°C, then
washed with IP buffer after incubation. RNA was extracted from the sample and
processed for qRT-PCR as described.
5.7 Antibody Delivery
Cells were incubated with the protein transduction mimic synthetic polymer P 13D5 at
1𝜇mol/l (Ozay et al., 2016) complexed to 25nmol/l of polyclonal anti-hnRNPLL (Invitrogen,
Carlsbad, CA) for 4 hours at 37°C. After incubation, cells were washed in 20U/mL of cold
heparin in PBS, then washed in PBS. Cells were resuspended in Th17 polarizing media
and differentiated as described.
5.8 RT-PCR
RNA was isolated from cells with the Quick-RNA Mini-Prep kit (Zymo Research). cDNA
was synthesized with Oligo(dt) 12-18 primer (ThermoFisher Scientific), m-MLV reverse

98

transcriptase and RNasinⓇ plus inhibitor (Promega Corporation), and dNTPs (New
England Biolabs). RT-PCR reactions were performed with Phusion polymerase (New
England Biolabs). The reactions were run on a Mastercycler Thermal Cycler (Eppendorf).
The samples were resolved on a 2% agarose gel.
5.9 Dichloroacetate (DCA) Treatment
Th17 cells were differentiated in Th17 polarization media for 5 days. On day 5, 10mM of
DCA (Gerriets et al., 2015) was added to the culture and cells were harvested 48 hours
later.
5.10 Immunoprecipitation
Cells were lysed in IP Buffer (Tris-HCL pH 8.0, 200nM NaCl, 0.1% NP-40) in the presence
of phosphatase and protease inhibitors (Bimake) and RNasin Ⓡ plus inhibitor (Promega).
Dynabeads protein GⓇ (ThermoFisher Scientific) were coated with anti-hnRNPLL (Cell
Signaling Technologies) at room temperature in a solution of 1% BSA (Rocky Mountain
Biologicals) in PBS. Lysates and beads were incubated together for 1 hour at 4°C, then
washed with IP buffer after incubation. Protein lysates were resolved on an 8% SDSPAGE gel and transferred onto a nitrocellulose membrane and blocked with 5% non-fat
milk dissolved in 0.2% Tween-20 in PBS.
5.11 Cytoplasmic and Nuclear Extract Isolation
Protein lysates were extracted using the NER-PERTM Nuclear and Cytoplasmic Extraction
Reagents (ThermoFisher Scientific). These lysates were then used according to the
immunoblot protocol.

99

5.12 STORM Microscopy
Cells were placed on poly-d-lysine coated plate (MatTeK) for 1 hour at room temperature.
Cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer
Set (eBioscience). Cells were stained with LKB1 Ley37D/G6 AF488 and Notch1 mN1a
AF647 (both from Santa Cruz Biotechnologies). Images were analyzed with NIS elements
and Matlab.
5.13 Statistics
Data are the mean ± SEM; all experiments were repeated at least three times. Unpaired,
two-tailed Student’s t-test and two-way ANOVA with post-Bonferroni test were applied for
statistical comparison using GraphPad Prism 8 software.
considered significant.
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p values of ≤ 0.05 were

Table 5.1 Antibodies used in this study
Target

Clone

Company

hamster IgG

Polyclonal

Sigma-Aldrich

CD3e

145-2C11

Biolegend

CD28

37.51

BD Biosciences

IFNg

XMG 1.2

BioXcell

IL-4

41B11

Biolegend

IL-4

41B11

BioXcell

CD4

H129.19

BD Biosciences

CD25

PC96

BD Biosciences

Foxp3

FJK-16s

BD Biosciences

Foxp3

150D

BD Biosciences

LKB1

D60C5

Cell Signaling Technologies

LKB1

Ley37D/G6

Santa Cruz Biotechnology

RORgT

AFKJS-9

eBioscience

F(ab’)2 IgG

Life Technologies

hnRNPLL

Polyclonal

Cell Signaling Technologies

hnRNPLL

Polyclonal

Invitrogen

a-tubulin

Polyclonal

Cell Signaling Technologies

mouse IgG HRP

Polyclonal

GE Amersham

rabbit IgG HRP

Polyclonal

GE Amersham

rabbit IgG HRP

Polyclonal

Cell Signaling Technologies

HnRNPL

4D11

Novus Biologicals
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Table 5.2 Primers used in this study
Primer Name
Stk11 Common
Stk11L
Stk11S
Hnrnpll
Il17f
Prkcq
Rorc
Foxp3
ActB
Ptprc

Forward Sequence
GACTCCGAGACCTTATGCCG
CATTATCTACACCCAGGACTTCACA
CCTGCAAGCAGCAGTGAC
GTGACGAGTACGCTGTGGAA
GAGGATAACACTGTGAGAGTTGAC
ATGGACAACCCCTTCTACCC
CACGGCCCTGGTTCTCAT
CTTATCCGATGGGCCATCCTGGAAG
GGCTGTATTCCCCTCCATCG
GGCAACACCTACACCCA
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Reverse Sequence
TTCTTGACGTTGGCCTCTCC
CGCATGCATCCTCGCTAA
CCAACGTCCCGAAGTGAG
CTGGGAACAACTGAGTGCTG
GAGTTCATGGTGCTGTCTTCC
GCGGATGTCTCCTCTCACTC
GCAGATGTTCCACTCTCCTCTTCT
TTCCAGGTGGCGGGGTGGTTTCTG
CCAGTTGGTAACAATGCCATGT
GCTTGCAGGCCCAGA
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